Management of chronic musculoskeletal pain in Hong Kong

© Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
 
EDITORIAL
Management of chronic musculoskeletal pain in Hong Kong
Regina WS Sit, FHKAM (Family Medicine), MD1; SW Law, MB, ChB, FHKAM (Orthopaedic Surgery)2,3; CY Lam, FHKAM (Orthopaedic Surgery), MPH4; Martin CS Wong, MD, MPH1
1 The JC School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong
2 Department of Orthopaedics and Traumatology, The Chinese University of Hong Kong, Hong Kong
3 The Hong Kong College of Orthopaedic Surgeons, Hong Kong
4 Department of Orthopaedics and Traumatology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong
 
Corresponding author: Dr Regina WS Sit (reginasit@cuhk.edu.hk)
 
 Full paper in PDF
 
Chronic musculoskeletal pain is a common and disabling condition, with significant physical, psychological, and social impairments.1 According to the Census and Statistics Department of the Hong Kong Special Administrative Region, it is estimated that the number of Hong Kong residents aged ≥65 years will increase from 0.9 million in 2011 (13% of the population) to around 2.6 million in 2041 (30% of the projected population).2 A local study in 2016 reported the prevalence of chronic pain of 28.7% in the general population; 83.1% reported more than one site of pain, and 5.8% reported eight or more sites of pain around the body.3 The prevalence is higher in the older population, with 70% adults aged ≥60 years reported having chronic pain of moderate intensity; the most common sites were the knee (48.3%), back (34.7%), and shoulder (28.1%).4 It is expected that individual and socio-economic burdens of chronic musculoskeletal pain will increase with the ageing population in Hong Kong, requiring a multi-level integrated response.
 
Management of chronic musculoskeletal pain in Hong Kong
Chronic musculoskeletal pain is commonly encountered in primary care.5 The role of primary care physicians is to assess, to diagnose and to manage treatable and modifiable causes. They also act as gatekeepers, identifying suitable candidates for secondary care. More importantly, primary care physicians help individuals with chronic pain to maintain the optimal quality of life.6 Chronic musculoskeletal pain, whether a result of trauma, infection, tumours, or other orthopaedic conditions with surgical implications, is managed by orthopaedic surgeons. For refractory pain, patients will be referred to pain clinics for more invasive interventions such as nerve blocks or spinal injections.7 The majority of residents in Hong Kong have Chinese ethnicity, so traditional Chinese medicine also plays an important role in the care of chronic musculoskeletal pain with treatments such as acupuncture and joint manipulation.8 Other allied health professionals, such as physiotherapists, occupational therapists, pain nurses, dietitians, psychologists, pharmacists, prosthetists, and orthotists also contribute substantially to the management and rehabilitation of various chronic musculoskeletal pain conditions. Despite having groups of experts in different fields in Hong Kong, there are major challenges to pain care, including over-reliance on the biomedical view of pain, inadequate emphasis on the biopsychosocial approach, a lack of service models to streamline communication, and a lack of cooperation and collaboration among disciplines.
 
Multidisciplinary care for chronic musculoskeletal pain
As healthcare systems internationally and in Hong Kong shift from promoting biomedical models of chronic pain to biopsychosocial models, multidisciplinary or interdisciplinary pain management models are encouraged.9 The team consists of multiple health providers from different disciplines with sufficient professional breadth that integrates through frequent communication and common goals to comprehensively address the biopsychosocial model of pain.10 The treatment- and cost-effectiveness of such pain management programmes have been well documented in the scientific literature, and their implementations have been successful.11 However, most of these programmes have been operated either in secondary or even tertiary care, where pain conditions are already chronic, complicated, and refractory. Therefore, we believe effective models of care should also be implemented in primary care. Timely and comprehensive management initiated in primary care can potentially avoid the course of development into chronicity. One example is “Turning Pain into Gain”,12 a multidisciplinary chronic pain programme implemented in one of the Primary Health Network in South East Queensland, Australia. This programme resulted in significant improvements in medication management, participant self-efficacy, and self-reported hospitalisations.12
 
Newer concepts for model development
The traditional model of medicine and medical science, which attempts to attribute musculoskeletal symptoms to a pathological diagnosis, has hindered the development of a more rational and effective approach to chronic pain care. This approach considers pain as the only guide to the underlying pathology and overemphasises diagnosis and attempts at cure. This approach ignores the status of pain and its related disability which warrant assessment and management of its own.13 There is a conceptual shift to place symptoms and their impact on daily life at the centre of primary care management.14 Furthermore, care should focus on individuals with co-morbidity rather than a distinctive single musculoskeletal diagnosis, incorporating psychological and social context in the management.15 Musculoskeletal pain is almost inevitable in the lifetime of an individual,16 and the resulting disability may diminish the opportunity for active and positive approaches to care. Therefore, promotion of active self-management, exercise and positive thinking are essential in supporting individuals with chronic pain.17 18 Platforms that facilitate communication between physicians, surgeons, and allied healthcare professionals enhance knowledge exchange and ultimately improve chronic pain care.19 Because managing chronic musculoskeletal pain is one of the largest workloads in primary care, knowledge, training, and enthusiasm must be strengthened.6 14 Other directions are possible alternatives, such as supporting and training healthcare professionals other than doctors to undertake the role of gatekeeper, such as permitting direct access for patients to advice from physiotherapists and pharmacists. These could be especially effective in areas where access to medical care is difficult.20 21
 
Reference framework of chronic musculoskeletal management in primary care
In addition to shifts in focus from unidisciplinary to multidisciplinary care, from passive treatment to active self-management, and from the complete cure of pain to living with the pain, another important change is from secondary to primary care. Primary care management should be holistic and evidence-based. Recent high-quality guidelines are available; however, there continues to be a relative lack of high-quality primary care–focused research in chronic pain. Further education, research, and resourcing targeted at primary care management of chronic pain are required to ensure efficient and effective evidence-based care. To facilitate all these, a task force formed by a group of experts is now working on a new reference framework for chronic musculoskeletal pain management in primary care settings. This reference framework aims to identify guidelines, models, and projects that represent the most comprehensive approach to managing chronic musculoskeletal pain, using the best available evidence that is relevant to the local healthcare context. The framework will determine successful elements in treating chronic musculoskeletal pain, as well as preventive strategies and blueprints for the promotion of overall musculoskeletal health.
 
Author contributions
All authors contributed to the Editorial, approved the final version for publication, and take responsibility for its accuracy and integrity.
 
Conflicts of interest
All authors have disclosed no conflicts of interest.
 
Funding/support
This editorial received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
 
References
1. Cimmino MA, Ferrone C, Cutolo M. Epidemiology of chronic musculoskeletal pain. Best Pract Res Clin Rheumatol 2011;25:173-83. Crossref
2. Hong Kong Population Projections 2015-2064. Census and Statistics Department, Hong Kong SAR Government; 2015.
3. Cheung CW, Choi SW, Wong SS, Lee Y, Irwin MG. Changes in prevalence, outcomes, and help-seeking behavior of chronic pain in an aging population over the last decade. Pain Pract 2017;17:643-54. Crossref
4. Sit RW, Zhang D, Wang B, et al. Sarcopenia and chronic musculoskeletal pain in 729 community-dwelling Chinese older adults with multimorbidity. J Am Med Dir Assoc 2019;20:1349-50. Crossref
5. Mose S, Kent P, Smith A, Andersen JH, Christiansen DH. Trajectories of musculoskeletal healthcare utilization of people with chronic musculoskeletal pain—a population-based cohort study. Clin Epidemiol 2021;13:825-43. Crossref
6. Mills S, Torrance N, Smith BH. Identification and management of chronic pain in primary care: a review. Curr Psychiatry Rep 2016;18:22. Crossref
7. Chu MC, Law RK, Cheung LC, et al. Pain management programme for Chinese patients: a 10-year outcome review. Hong Kong Med J 2015;21:304-9. Crossref
8. Vickers AJ, Vertosick EA, Lewith G, et al. Acupuncture for chronic pain: update of an individual patient data meta-analysis. J Pain 2018;19:455-74. Crossref
9. Gatchel RJ, McGeary DD, McGeary CA, Lippe B. Interdisciplinary chronic pain management: past, present, and future. Am Psychol 2014;69:119-30. Crossref
10. Stanos S, Houle TT. Multidisciplinary and interdisciplinary management of chronic pain. Phys Med Rehabil Clin N Am 2006;17:435-50. Crossref
11. Kamper SJ, Apeldoorn AT, Chiarotto A, et al. Multidisciplinary biopsychosocial rehabilitation for chronic low back pain: Cochrane systematic review and meta-analysis. BMJ 2015;350:h444. Crossref
12. Joypaul S, Kelly FS, King MA. Turning pain into gain: evaluation of a multidisciplinary chronic pain management program in primary care. Pain Med 2019;20:925-33. Crossref
13. Clauw DJ, Essex MN, Pitman V, Jones KD. Reframing chronic pain as a disease, not a symptom: rationale and implications for pain management. Postgrad Med 2019;131:185-98. Crossref
14. Croft P, Peat GM, Van Der Windt DA. Primary care research and musculoskeletal medicine. Prim Health Care Res Dev 2010;11:4-16. Crossref
15. Bergman S. Management of musculoskeletal pain. Best Pract Res Clin Rheumatol 2007;21:153-66. Crossref
16. Walsh NE, Brooks P, Hazes JM, et al. Standards of care for acute and chronic musculoskeletal pain: the Bone and Joint Decade (2000-2010). Arch Phy Med Rehabil 2008;89:1830-45. Crossref
17. Du S, Yuan C, Xiao X, Chu J, Qiu Y, Qian H. Self-management programs for chronic musculoskeletal pain conditions: a systematic review and meta-analysis. Patient Educ Couns 2011;85:e299-310. Crossref
18. Reid MC, Papaleontiou M, Ong A, Breckman R, Wethington E, Pillemer K. Self-management strategies to reduce pain and improve function among older adults in community settings: a review of the evidence. Pain Med 2008;9:409-24. Crossref
19. Gordon DB, Watt-Watson J, Hogans BB. Interprofessional pain education—with, from, and about competent, collaborative practice teams to transform pain care. Pain Rep 2018;3:e663. Crossref
20. Bury TJ, Stokes EK. A global view of direct access and patient self-referral to physical therapy: implications for the profession. Phys Ther 2013;93:449-59. Crossref
21. Hadi MA, Alldred DP, Briggs M, Munyombwe T, José Closs S. Effectiveness of pharmacist-led medication review in chronic pain management: systematic review and meta-analysis. Clin J Pain 2014;30:1006-14. Crossref

Cardiovascular complications of COVID-19: a future public health burden requiring intensive attention and research

© Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
 
EDITORIAL
Cardiovascular complications of COVID-19: a future public health burden requiring intensive attention and research
Bryan P Yan, MB, BS, MD1; Martin CS Wong, MD, MPH2,3
1 Division of Cardiology, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong
2 JC School of Public Health and Primary Care, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong
3 Editor-in-Chief, Hong Kong Medical Journal
 
Corresponding author: Prof Martin CS Wong (wong_martin@cuhk.edu.hk)
 
 Full paper in PDF
 
Although coronavirus disease 2019 (COVID-19) is primarily a respiratory disease, cardiovascular complications are frequent in patients with COVID-19 and are associated with poor prognosis.1 Myocardial injury, defined as elevation of serum troponin level, is one of the most common extrapulmonary complications of COVID-19.2 The incidence of cardiac injury increases with severity of disease (62.9% in severe cases vs 17.9% in mild),2 and with age (4% <60 years vs 12.5% 60-74 years vs 31% ≥75 years in age).3 Elevated troponin levels are associated with increased intensive care unit admission and worse prognosis.4 5 As the COVID-19 pandemic evolves and variants emerge, a clear understanding regarding the short- and long-term effects of COVID-19 on the cardiovascular system and outcomes is urgently needed.
 
In this issue of Hong Kong Medical Journal, Lo et al6 review the literature on cardiac injury associated with COVID-19. This review is both timely and important for us to better understand the pathogenesis of cardiac injury and the implications for treatment. Most studies included in this review reported cardiovascular complications during the acute phase of infection; however, recent data have shown that COVID-19 can cause cardiovascular symptoms, such as shortness of breath and palpitations. These symptoms can last weeks or months after the infection has gone. This is sometimes called post-COVID-19 syndrome or “long COVID”.7 A recent study has shown that the risk and 1-year burden of cardiovascular disease, including cerebrovascular disorders, dysrhythmias, ischemic and non–ischaemic heart disease, pericarditis, myocarditis, heart failure, and thromboembolic disease in survivors of acute COVID-19 are substantial.7 Patients with severe COVID-19 who need to be admitted to hospital or intensive care unit are at higher risk; however, even people with mild disease who do not need hospitalisation are also at increased risk of cardiovascular diseases 6 months to 1 year later.7 There is still a lot to learn about the lasting effects COVID-19 has had on the heart. Among magnetic resonance imaging scans of patients who recovered from COVID-19, the majority (78/100) showed abnormal findings suggestive of ongoing inflammation and scarring on the heart muscle.8 The virus may leave behind lasting heart damage that needs monitoring in some patients.
 
Since the emergence of the new Omicron variant in November 2021, experts have been trying to learn more about this variant and the risks it poses in the long term. The Omicron variant is highly transmissible which might mean an increase in cases, leading to more hospitalisations, cardiovascular complications, and deaths. The long-term cardiovascular effects of this variant are less well understood and are yet be addressed.
 
Physicians should consider a history of COVID-19 as a cardiovascular disease risk. It is important to identify early signs or symptoms of heart disease in these people. Early detection, diagnosis, and treatment will be key to prevent downstream adverse cardiovascular consequences. There are a lot of knowledge gaps that need to be investigated in future research to gain a better understanding of long-term cardiovascular outcomes of patients with COVID-19. How best to identify, diagnose, and treat these patients is a critical area of future research. The long-term trajectory of cardiovascular diseases among patients with COVID-19 requires long-term cohort studies to guide clinical practice and inform public health policy. An important message is increased awareness of cardiovascular complications among patients with COVID-19 and having well-established follow-up strategies.
 
Author contributions
All authors contributed to the editorial, approved the final version for publication, and take responsibility for its accuracy and integrity.
 
Conflicts of interest
The authors have declared no conflict of interest.
 
References
1. Welty FK, Rajai N, Amangurbanova M. Comprehensive review of cardiovascular complications of coronavirus disease 2019 and beneficial treatments. Cardiol Rev 2022;30:145-57. Crossref
2. Li T, Lu L, Zhang W, et al. Clinical characteristics of 312 hospitalized older patients with COVID-19 in Wuhan, China. Arch Gerontol Geriatr 2020;91:104185. Crossref
3. Zhao M, Wang M, Zhang J, et al. Comparison of clinical characteristics and outcomes of patients with coronavirus disease 2019 at different ages. Aging (Albany NY) 2020;12:10070-86. Crossref
4. Lala A, Johnson KW, Januzzi JL, et al. Prevalence and impact of myocardial injury in patients hospitalized with COVID-19 infection. J Am Coll Cardiol 2020;76:533-46. Crossref
5. Ni W, Yang X, Liu J, et al. Acute myocardial injury at hospital admission is associated with all-cause mortality in COVID-19. J Am Coll Cardiol 2020;76:124-5. Crossref
6. Lo YS, Jok C, Tse HF. Cardiovascular complications of COVID-19. Hong Kong Med J 2022;28:249-56. Crossref
7. Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med 2022;28:583-90. Crossref
8. Puntmann VO, Carerj ML, Wieters I, et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020;5:1265-73. Crossref

COVID-19 pandemic after Omicron

© Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
 
EDITORIAL
COVID-19 pandemic after Omicron
Christopher KC Lai, FHKCPath, FHKAM (Pathology)1; Wilson Lam, FRCP, FHKAM (Medicine)2; KY Tsang, FRCP (Edin), FHKAM (Medicine)3; Frankie WT Cheng, FRCPCH, MD4; Martin CS Wong, MD, MPH5,6
1 Department of Microbiology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong
2 Chiron Medical, Hong Kong
3 Specialist in Infectious Disease, Private Practice, Hong Kong
4 Department of Paediatrics and Adolescent Medicine, Hong Kong Children’s Hospital, Hong Kong
5 JC School of Public Health and Primary Care, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong
6 Editor-in-Chief, Hong Kong Medical Journal
 
Corresponding author: Prof Martin CS Wong (wong_martin@cuhk.edu.hk)
 
 Full paper in PDF
 
At the time of writing, the “fifth wave” of coronavirus disease 2019 (COVID-19) in Hong Kong that started to surge since late January 2022 is receding. The fifth wave has been the worst so far, with daily cases exceeding 55 000, and total >9000 deaths.1 Epidemiological studies predicted that 4.5 to 5 million people in Hong Kong would have contracted COVID-19 by the end of the wave.2 However, as the pandemic progresses, more people will gain immunity against the virus through vaccination or natural infection, or both (hybrid immunity). Together with a community-wide intersectoral effort to boost vaccination uptake, the COVID-naïve population in Hong Kong will decline rapidly, and so will the transmission efficiency of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It seems we are set to cruise back to pre-COVID normalcy. Or are we?
 
Since its emergence in late 2019, SARS-CoV-2 has mutated at an astounding rate. Omicron has evolved to be the most transmissible variant so far, fortunately causing less severe disease than its predecessors.3 Will Omicron stay as the predominant variant, or will new variants emerge causing fresh waves? Despite the waning of the current Omicron wave, SARS-CoV-2 continues to spread in almost every corner of the world. The huge number of infections has provided near ideal conditions for new variants to emerge, as we have seen in the Delta4 and Omicron variants.5 One of the latest recombinants of Omicron BA.1 and BA.2 strain known as XE is even more transmissible than Omicron BA.2.6 It seems likely that we are set to be challenged by more new variants, albeit with some degree of protection from immunity generated during previous infection or vaccination. Given that the virus is unlikely to disappear completely, COVID-19 will inevitably become an endemic disease. The COVID-19 vaccines are now well known to significantly lower disease severity and mortality, and have saved millions of lives worldwide. Despite the proven efficacy and safety profile, vaccine hesitancy remains a concern.7 Moreover, it is now increasingly evident that COVID-19 vaccines are not going to halt the pandemic. Infections still occur in fully vaccinated individuals,8 and antibody level is known to decrease over time.9
 
In the past 2 years, the Hong Kong Medical Journal has published >60 COVID-19-related papers. We foresee that the need for COVID-19-related studies will remain. Future research directions will be realigned as the pandemic unfolds, with vaccine-related research in the highest demand. In 2021, the Journal published a serological response to mRNA and inactivated vaccines in healthcare workers in Hong Kong,10 and reported cases of myocarditis and pericarditis after mRNA vaccines.11 New vaccines in novel platforms or targeting new COVID-19 variants will continue to be developed, and research directed at monitoring the efficacy and adverse effects of these vaccines will remain important to guide vaccination strategies. Vaccine hesitancy remains a major hurdle in achieving herd immunity,7 12 and public health intervention studies involving various stakeholders in the community that can promote vaccine uptake will be highly sought.
 
In the earliest months of pandemic, the Journal published radiological findings of critically ill patients diagnosed with COVID-19,13 and a case series on contrasting evidence for corticosteroid treatment for COVID-19-induced cytokine storm in children.14 We anticipate publications on clinical management will remain invaluable to the medical community, perhaps with a shift in focus to greater emphasis on integrative treatment strategies,15 microbiome-based therapies, and prophylactic antiviral agents and monoclonal antibody therapies targeting vulnerable populations such as the paediatric population16 17 and immunocompromised hosts.
 
In 2021, the Journal published an editorial by Tse et al18 on the impact of COVID-19 on both physical health and mental health. We anticipate the need for further research in the areas of mental health and mental well-being during the COVID-19 pandemic.
 
Many COVID-19 survivors report persistence of symptoms after recovery. With an estimate of 4 to 5 million of the Hong Kong population infected with COVID-19,2 it is clear that more resources should be allocated to long COVID–related services and research. Systematic gathering of information on long COVID will allow accurate measurement of the disease burden and will be critical in facilitating future research. Establishment of designated one-stop multidisciplinary medical centres will allow individualised treatment and rehabilitation programmes, optimising the care of long COVID sufferers and providing a positive impact at the societal level. We will witness researchers moving from studying acute COVID infections to studying post-COVID-19 conditions in the near future.
 
Laboratory diagnostics played a crucial role in COVID-19 case findings, contact tracing, and outbreak investigations. Throughout the course of the COVID-19 pandemic we have witnessed the widespread use of state-of-the-art next-generation sequencing techniques in understanding the phylogeny and evolution of SARS-CoV-2.19 20 However, novelty does not necessarily require high-tech gadgets; a study by Zee et al21 illustrated how the use of rapid antigen tests can assist outbreak control in a hospital. With the rapid development of new laboratory techniques and novel ideas, we expect a huge amount of knowledge to be generated in this area.
 
Epidemiology and public health studies with forecasting ability can guide public policies. The Journal has published research articles on experiences of a temporary testing centre at the AsiaWorld-Expo,22 department-level contingency plans for contact tracing and facility management,23 and admission triage for adult intensive care.24
 
The waning fifth COVID wave gives us much-needed breathing space to plan ahead. We have faced challenges in ensuring that the Hong Kong population is protected by vaccination and effective testing and tracing. We have experienced global supply chain disruption in key pandemic products, including vaccines, antivirals, personal protective equipment, and laboratory test kits and reagents. It is time to reflect on what we could have done if we knew COVID was coming, and to make it a reality for future pandemics. Pandemic preparedness requires a holistic approach from multiple disciplines to provide a comprehensive and generalisable preparedness plan.25 A recent article by Morens et al26 suggested that “controlling COVID-19 by increasing herd immunity may be an elusive goal”. Research focusing on infectious disease epidemiology, public health policies, laboratory diagnostics, vaccine development, and drug discovery will remain in high demand. Future research will need to be synergistic and able to coalesce into a strong healthcare system, to defend against subsequent COVID waves and future pandemics.
 
Author contributions
All authors contributed to the Editorial, approved the final version for publication, and take responsibility for its accuracy and integrity.
 
Funding/support
This editorial received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
 
Conflicts of interest
The authors have declared no conflict of interest.
 
References
1. Centre for Health Protection of the Department of Health; and the Hospital Authority. Statistics on 5th wave of COVID-19. 27 April 2022. Available from: https://www.covidvaccine.gov.hk/pdf/5th_wave_statistics.pdf. Accessed 28 Apr 2022.
2. The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong. Assessment of Omicron outbreak in Hong Kong. 20 April 2022. Available from: https://www.sphpc.cuhk.edu.hk/post/study-assessment-of-omicron-outbreak-in-hong-kong. Accessed 28 Apr 2022.
3. Centers for Disease Control and Prevention. Omicron variant: what you need to know. 29 March 2022. Available from: https://www.cdc.gov/coronavirus/2019-ncov/variants/omicron-variant.html. Accessed 28 Apr 2022.
4. Ferreira IA, Kemp SA, Datir R, et al. SARS-CoV-2 B.1.617 mutations L452R and E484Q are not synergistic for antibody evasion. J Infect Dis 2021;224:989-94. Crossref
5. Callaway E. Heavily mutated Omicron variant puts scientists on alert. Nature 2021;600:21. Crossref
6. UK Health Security Agency. SARS-CoV-2 variants of concern and variants under investigation in England. 25 March 2022 (updated 8 April 2022). Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1067672/Technical-Briefing-40-8April2022.pdf. Accessed 28 Apr 2022.
7. Chan PK, Wong MC, Wong EL. Vaccine hesitancy and COVID-19 vaccination in Hong Kong. Hong Kong Med J 2021;27:90-1. Crossref
8. Bergwerk M, Gonen T, Lustig Y, et al. Covid-19 breakthrough infections in vaccinated health care workers. N Engl J Med 2021;385:1474-84. Crossref
9. Lin DY, Zeng D, Gu Y, Krause PR, Fleming TR. Reliably assessing duration of protection for COVID-19 vaccines. J Infect Dis 2022 Apr 21;jiac139. Epub ahead of print. Crossref
10. Zee JS, Lai KT, Ho MK, et al. Serological response to mRNA and inactivated COVID-19 vaccine in healthcare workers in Hong Kong: decline in antibodies 12 weeks after two doses. Hong Kong Med J 2021;27:380-3. Crossref
11. Kwan MY, Chua GT, Chow CB, et al. mRNA COVID vaccine and myocarditis in adolescents. Hong Kong Med J 2021;27:326-7. Crossref
12. Chau CY. COVID-19 vaccination hesitancy and challenges to mass vaccination. Hong Kong Med J 2021;27:377-9. Crossref
13. Woo SC, Yung KS, Wong T, et al. Imaging findings of critically ill patients with COVID-19 pneumonia: a case series. Hong Kong Med J 2020;26:236-9. Crossref
14. Leung KK, Hon KL, Qian SY, Cheng FW. Contrasting evidence for corticosteroid treatment for coronavirusinduced cytokine storm. Hong Kong Med J 2020;26:269-71. Crossref
15. Lin WL, Hon KL, Leung KK, Lin ZX. Roles and challenges of traditional Chinese medicine in COVID-19 in Hong Kong. Hong Kong Med J 2020;26:268-9. Crossref
16. Hon KL, Leung KK. Paediatrics is a big player of COVID-19 in Hong Kong. Hong Kong Med J 2020;26:265-6. Crossref
17. Chua GT, Wong JS, Chung J, et al. Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2: a case report. Hong Kong Med J 2022;28:76-8. Crossref
18. Tse WW, Kwan MY. Impacts of the COVID-19 pandemic on the physical and mental health of children. Hong Kong Med J 2021;27:175-6. Crossref
19. Chen Z, Chong KC, Wong MC, et al. A global analysis of replacement of genetic variants of SARS-CoV-2 in association with containment capacity and changes in disease severity. Clin Microbiol Infect 2021;27:750-7. Crossref
20. Siu GK, Lee LK, Leung KS, et al. Will a new clade of SARS-CoV-2 imported into the community spark a fourth wave of the COVID-19 outbreak in Hong Kong? Emerg Microbes Infect 2020;9:2497-500.Crossref
21. Zee JS, Chan CT, Leung AC, et al. Rapid antigen test during a COVID-19 outbreak in a private hospital in Hong Kong. Hong Kong Med J 2022 Mar 17. Epub ahead of print. Crossref
22. Leung WL, Yu EL, Wong SC, et al. Findings from the first public COVID-19 temporary test centre in Hong Kong. Hong Kong Med J 2021;27:99-105. Crossref
23. Mak ST, Fung KS, Li KK. Formulation of a departmental COVID-19 contingency plan for contact tracing and facilities management. Hong Kong Med J 2021;27:148-9. Crossref
24. Joynt GM, Leung AK, Ho CM, et al. Admission triage tool for adult intensive care unit admission in Hong Kong during the COVID-19 outbreak. Hong Kong Med J 2022;28:64-72. Crossref
25. Wong AT, Chen H, Liu SH, et al. From SARS to avian influenza preparedness in Hong Kong. Clin Infect Dis 2017;64(suppl_2):S98-S104. Crossref
26. Morens DM, Folkers GK, Fauci AS. The concept of classical herd immunity may not apply to COVID-19. J Infect Dis 2022 Mar 31;jiac109. Epub ahead of print. Crossref

Kidney Health for All: bridging the gap in kidney health education and literacy

Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
 
EDITORIAL
Kidney Health for All: bridging the gap in kidney health education and literacy
Robyn G Langham, MB, BS, PhD1 #; Kamyar Kalantar-Zadeh, MD, PhD2 #; Ann Bonner, RN, PhD3; Alessandro Balducci, MD4 #; LL Hsiao, MD, PhD5 #; Latha A Kumaraswami, BA6 #; Paul Laffin, MS7 #; Vassilios Liakopoulos, MD, PhD8 #; Gamal Saadi, MD9 #; Ekamol Tantisattamo, MD, MPH2; Ifeoma Ulasi, MB, BS, MSc10 #; SF Lui, MD11 #; for the World Kidney Day Joint Steering Committee#
1 St Vincent’s Hospital, Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia
2 Division of Nephrology, Hypertension and Kidney Transplantation, Department of Medicine, University of California Irvine School of Medicine, Orange, California, United States
3 School of Nursing and Midwifery, Griffith University, Southport, Queensland, Australia
4 Italian Kidney Foundation, Rome, Italy
5 Brigham and Women’s Hospital, Renal Division, Department of Medicine, Boston, Massachusetts, United States
6 Tamilnad Kidney Research (TANKER) Foundation, The International Federation of Kidney Foundations–World Kidney Alliance (IFKF–WKA), Chennai, India
7 International Society of Nephrology, Brussels, Belgium
8 Division of Nephrology and Hypertension, First Department of Internal Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
9 Nephrology Unit, Department of Internal Medicine, Faculty of Medicine, Cairo University, Giza, Egypt
10 Renal Unit, Department of Medicine, College of Medicine, University of Nigeria, Ituku-Ozalla, Enugu, Nigeria
11 International Federation of Kidney Foundations–World Kidney Alliance, The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong
# Members of the World Kidney Day Steering Committee
 
Corresponding author: Dr Robyn G Langham (rlangham@unimelb.edu.au)
 
 Full paper in PDF
 
Abstract
The high burden of kidney disease, global disparities in kidney care, and poor outcomes of kidney failure bring a concomitant growing burden to persons affected, their families, and carers, and the community at large. Health literacy is the degree to which persons and organisations have or equitably enable individuals to have the ability to find, understand, and use information and services to make informed health-related decisions and actions for themselves and others. Rather than viewing health literacy as a patient deficit, improving health literacy largely rests with healthcare providers communicating and educating effectively in codesigned partnership with those with kidney disease. For kidney policy makers, health literacy provides the imperative to shift organisations to a culture that places the person at the centre of healthcare. The growing capability of and access to technology provides new opportunities to enhance education and awareness of kidney disease for all stakeholders. Advances in telecommunication, including social media platforms, can be leveraged to enhance persons’ and providers’ education; The World Kidney Day declares 2022 as the year of “Kidney Health for All” to promote global teamwork in advancing strategies in bridging the gap in kidney health education and literacy. Kidney organisations should work towards shifting the patient-deficit health literacy narrative to that of being the responsibility of healthcare providers and health policy makers. By engaging in and supporting kidney health–centred policy making, community health planning, and health literacy approaches for all, the kidney communities strive to prevent kidney diseases and enable living well with kidney disease.
 
Given the high burden of kidney disease and global disparities related to kidney care, in carrying forward our mission of advocating Kidney Health for All, the challenging issue of bridging the well-identified gap in the global understanding of kidney disease and its health literacy is the theme for World Kidney Day (WKD) 2022. Health literacy is defined as the degree to which persons and organisations have—or equitably enable individuals to have—the ability to find, understand, and use information and services to inform health-related decisions and actions for themselves and others.1 Not only is there is growing recognition of the role that health literacy has in determining outcomes for persons affected by kidney disease and the community in general, but there is an emergent imperative for policy makers worldwide to be informed and cognizant of opportunities and real measurable outcomes that can be achieved through kidney-specific preventative strategies.
 
The global community of people with kidney disease
Most people are not aware of what kidneys are for or even where their kidneys are. For those afflicted by disease and the subsequent effects on overall health, effective healthcare provider communication is required to support individuals to be able to understand what to do, to make decisions, and to take action. Health literacy involves more than functional abilities of an individual; it is also the cognitive and social skills needed to gain access to, understand, and use information to manage health conditions.2 It is also contextual3 in that as health needs change, so too does the level of understanding and ability to problem solve alter. Health literacy is, therefore, an interaction between individuals, healthcare providers, and health policy makers.4 This is why the imperatives around health literacy are now recognised as indicators for the quality of local and national healthcare systems and healthcare professionals within them.5 For chronic kidney disease (CKD), as the disease progresses alongside other health changes and increasing treatment complexities, it becomes more difficult for individuals to manage.6 Promoted in health policy for around a decade involving care partnerships between health-centred policy, community health planning, and health literacy,7 current approaches need to be shifted forward (Table 1).
 

Table 1. Summary characteristic of kidney health promotion, involving kidney health–centred policy, community kidney health planning, and kidney health literacy, and proposed future direction
 
Assessing health literacy necessitates the use of appropriate multidimensional patient-reported measures, such as the World Health Organization–recommended Health Literacy Questionnaire (available in over 30 languages) rather than tools measuring only functional health literacy (eg, Rapid Estimate of Adult Literacy in Medicine or Short Test of Functional Health Literacy in Adults).8 It is therefore not surprising that studies of low health literacy (LHL) abilities in people with CKD have been demonstrated to be associated with poor CKD knowledge, self-management behaviours, and health-related quality of life and in those with greater co-morbidity severity.7 Unfortunately, most CKD studies have measured only functional health literacy, so the evidence that LHL results in poorer outcomes, particularly that it increases healthcare utilisation and mortality9 and reduces access to transplantation,10 is weak.
 
Recently, health literacy is now considered to be an important bridge between lower socioeconomic status and other social determinants of health.4 Indeed, this is not a feature that can be measured by the gross domestic product of a country, as the effects of LHL on the extent of CKD in the community are experienced globally regardless of country income status. The lack of awareness of risk factors of kidney disease, even in those with high health literacy abilities, is a testament to the difficulties in understanding this disease, and why the United States, for instance, recommends that a universal precautions approach towards health literacy is undertaken.11
 
So, what does the perfect health literacy programme look like for people with CKD? In several high-income countries, there are national health literacy action plans with the emphasis shifted to policy directives, organisational culture, and healthcare providers. In Australia, for instance, a compulsory health literacy accreditation standard makes the healthcare organisation responsible for ensuring providers are cognizant of individual health literacy abilities.12 Although many high-income countries, healthcare organisations, non-governmental organisations, and jurisdictions are providing an array of consumer-facing web-based programmes that provide detailed information and self-care training opportunities, most are largely designed for individual/family use that are unlikely to mitigate LHL. There is, however, substantial evidence that interventions improving healthcare provider communication are more likely to improve understanding of health problems and abilities to adhere to complex treatment regimens.13
 
Access to information that is authentic and tailored specifically to the needs of the individual and the community is the aim. The challenge is recognised acutely in more remote and low- to middle-income countries of the world, specifically the importance of culturally appropriate knowledge provision. The principles of improving health literacy are the same, but understanding how to proceed, and putting consumers in charge, with a co-design approach, is critical and may result in a different outcome in more remote parts of the world. This principle especially applies to communities that are smaller, with less access to electronic communication and healthcare services, where the level of health literacy is shared across the community and where what affects the individual also affects all the community. Decision support systems are different, led by elders, and in turn educational resources are best aimed at improving knowledge of the whole community.
 
A systematic review of the evaluation of interventions and strategies shows this area of research is still at an early stage,14 with no studies unravelling the link between LHL and poor CKD outcomes. The best evidence is in supporting targeted programmes on improving communication capabilities of healthcare professionals as central. One prime example is ‘teach-back’, a cyclical, simple, low-cost education intervention, which shows promise for improving communication, knowledge, and self-management in the CKD populations in low- or high-income countries.15 Furthermore, the consumer-led voice has articulated research priorities that align closely with principles felt to be important to the success of education: building new education resources, devised in partnership with consumers, and focussed on the needs of vulnerable groups. Indeed, programmes that address the lack of culturally safe, person-centred and holistic care, along with improving the communication skills of health professionals, are crucial for those with CKD.16
 
The networked community of kidney healthcare workers
Nonphysician healthcare workers, including nurses and advanced practice providers (physician assistants and nurse practitioners) as well as dietitians, pharmacists, social workers, technicians, physical therapists, and other allied health professionals, often spend more time with persons with kidney disease, compared with nephrologists and other physician specialists. In an ambulatory care setting at an appointment, in the emergency department, or in the in-patient setting, these healthcare professionals often see and relate to the patient first, last, and in between, given that physician encounters are often short and focused. Hence, the nonphysician healthcare workers have many opportunities to discuss kidney disease-related topics with the individuals and their care partners and to empower them.17 18 For instance, medical assistants can help identify those with or at risk of developing CKD and can initiate educating them and their family members about the role of diet and lifestyle modification for primary, secondary, and tertiary prevention of CKD while waiting to see the physician.19 Some healthcare workers provide networking and support for kidney patient advocacy groups and kidney support networks, which have been initiated or expanded via social media platforms (Fig 1).20 21 Studies examining the efficacy of social media in kidney care and advocacy are on the way.22 23
 

Figure 1. Schematic representation of consumer and healthcare professionals’ collaborative advocacy using social media platforms with the goal of ‘Kidney Health for All’
 
Like physicians, many activities of nonphysician healthcare workers have been increasingly affected by the rise of electronic health recording and growing access to internet-based resources, including social media, that offer educational materials related to kidney health, including kidney-preserving therapies with traditional and emerging interventions.24 These resources can be used for both self-education and for networking and advocacy on kidney disease awareness and learning. Increasingly, more healthcare professionals are engaged in some types of social media-based activities, as shown in Table 2. At the time of this writing, the leading social media used by many—but not all—kidney healthcare workers include Facebook, Instagram, Twitter, LinkedIn, and YouTube. In some regions of the world, certain social media are more frequently used than others given unique cultural or access constellations (eg, WeChat is a platform often used by healthcare workers and patient groups in China). Some healthcare professionals, such as managers and those in leadership and advocacy organisation positions, may choose to embark on social media to engage those with CKD and their care partners or other healthcare professionals in alliance building and marketing. To that end, effective communication strategies and outreach skills specific to responsible use of social media can provide clear advantages given that these skills and strategies are different and may need modification in those with LHL. It is imperative to ensure the needed knowledge and training for an accountable approach to social media is provided to healthcare providers, so that these outreach strategies are utilised with the needed awareness of their unique strengths and pitfalls, as follows.25
 

Table 2. Social media that are more frequently used for kidney education and advocacy
 
(i) Consumers’ and care partners’ confidentiality may not be breached upon posting anything on social media, including indirect referencing to a specific individual or a particular description of a condition unique to a specific person (eg, upon soliciting for transplant kidney donors on social media).26 27
ii) Confidential information about clinics, hospitals, dialysis centres, or similar healthcare and advocacy entities may not be disclosed on social media without ensuring that the needed processes, including collecting authorisations to disclose, are undertaken.
(iii) Healthcare workers’ job security and careers should remain protected with thorough review of the content of the messages and illustrations/videos before online posting.
(iv) Careless and disrespectful language and emotional tones are often counterproductive and may not be justified under the context of freedom of speech.
 
The global kidney community of policy and advocacy
Policy and advocacy are well-recognised tools that, if properly deployed, can bring about change and paradigm shift at the jurisdictional level. The essence of advocating for policy change to better address kidney disease is, in itself, an exercise in improving health literacy of the policy makers. Policy development, at its core, is a key stakeholder or stakeholder group (eg, the kidney community, which believes that a problem exists that should be tackled through governmental action). There is increasing recognition of the importance of formulating succinct, meaningful, and authentic information, akin to improving health literacy, to present to governments for action.
 
Robust and efficacious policy is always underpinned by succinct and applicable information; however, the development and communication of this message, designed to bridge the gap in knowledge of relevant jurisdictions, is only part of the process of policy development. An awareness of the process is important to clinicians who are aiming to advocate for effective change in prevention or improvement of outcomes in the CKD community.
 
Public policies, the plans for future action accepted by governments, are articulated through a political process in response to stakeholder observation, usually written as a directive, law, regulation, procedure, or circular. Policies are purpose fit and targeted to defined goals and specific societal problems and are usually a chain of actions effected to solve those societal problems.28 Policies are an important output of political systems. Policy development can be formal, passing through rigorous lengthy processes before adoption (such as regulations), or it can be less formal and quickly adopted (such as circulars). As already mentioned, the governmental action envisaged by the key stakeholders as a solution to a problem is at its core. The process enables stakeholders to air their views and bring their concerns to the fore. Authentic information that is meaningful to the government is critical. The policy development process can be stratified into five stages (ie, the policy cycle), as depicted by Anderson (1994)29 and adapted and modified by other authors30 (Fig 2). The policy cycle constitutes an expedient framework for evaluating the key components of the process.
 

Figure 2. Policy cycle involving five stages of policy development
 
Subsequently, the policy moves on to the implementation phase. This phase may require subsidiary policy development and adoption of new regulations or budgets (implementation). Policy evaluation is integral to the policy processes and applies evaluation principles and methods to assess the content, implementation, or impact of a policy. Evaluation facilitates understanding and appreciation of the worth and merit of a policy as well as the need for its improvement. More important, of the five principles of advocacy that underline policy making,31 the most important for clinicians engaged in this space is that of commitment, persistence, and patience. Advocacy takes time to yield the desired results.
 
The Advocacy Planning Framework, developed by Young and Quinn in 2002, 30 consists of overlapping circles representing three sets of concepts (way into the process, the messenger, and message and activities) that are key to planning any advocacy campaign:
 
(i) “Way into the process”: discusses the best approaches to translate ideas into the target policy debate and identify the appropriate audience to target.
(ii) Messenger: talks about the image maker or face of the campaign and other support paraphernalia that are needed.
(iii) Message and activities: describe what can be said to the key target audiences that is engaging and convincing. And how best it can be communicated through appropriate communication tools.
 
Advocacy is defined as “an effort or campaign with a structured and sequenced plan of action which starts, directs, or prevents a specific policy change.”31 The goal being to influence decision makers through communicating directly with them or getting their commitment through secondary audiences (advisers, the media, or the public) to the end that the decision maker understands, is convinced, takes ownership of the ideas, and finally has the compulsion to act.31 As with improving health literacy, it is the communication of ideas to policy makers for adoption and implementation as policy that is key. There is much to be done with bridging this gap in understanding of the magnitude of community burden that results from CKD. Without good communication, many good ideas and solutions do not reach communities and countries where they are needed. Again, aligned with the principles of developing resources for health literacy, the approach also needs to be nuanced according to the local need, aiming to have the many good ideas and solutions be communicated to communities and countries where they are needed
 
Advocacy requires galvanising momentum and support for the proposed policy or recommendation. The process is understandably slow as it involves discussions and negotiations for paradigms, attitudes, and positions to shift. In contemplating advocacy activities, multiple factors must be considered, interestingly not too dissimilar to that of building health literacy resources: What obstructions are disrupting the policy making process from making progress? What resources are available to enable the process to succeed? Is the policy objective achievable considering all variables? Is the identified problem already being considered by the policy makers (government or multinational organisations)? Any interest or momentum generated around it? Understandably, if there is some level of interest and if governments already have a spotlight on the issue, it is likely to succeed.
 
Approaches to choose from include the following31 32:
  • Advising (researchers are commissioned to produce new evidence-based proposals to assist the organisation in decision making).
  • Activism: involves petitions, public demonstrations, posters, fliers, and leaflet dissemination, often used by organisations to promote a certain value set.
  • Media campaign: having public pressure on decision makers helps in achieving results
  • Lobbying: entails face-to-face meetings with decision makers; often used by business organisations to achieve their purpose.
  •  
    Here lies the importance of effective and successful advocacy to stakeholders, including policy makers, healthcare professionals, communities, and key change makers in society. The WKD, since inception, has aimed at playing this role. World Kidney Day has gained people’s trust by delivering relevant and accurate messaging and supporting leaders in local engagement, and it is celebrated by kidney care professionals, celebrities, those with the disease, and their caregivers all over the world. To achieve the goal, an implementation framework of success in a sustainable way includes creativity, collaboration, and communication.
     
    The ongoing challenge for the International Society of Nephrology and International Federation of Kidney Foundations—World Kidney Alliance, through the Joint Steering Committee of WKD, is to operationalise how to collate key insights from research and analysis to effectively feed the policy making process at the local, national, and international levels, to inform or guide decision making (ie, increasing engagement of governments and organisations, like World Health Organization, United Nations, and regional organisations, especially in low-resource settings). There is a clear need for ongoing renewal of strategies to increase efforts at closing the gap in kidney health literacy, empowering those affected with kidney disease and their families, giving them a voice to be heard, and engaging with civil society. This year, the Joint Steering Committee of WKD declares “Kidney Health for All” as the theme of the 2022 WKD to emphasise and extend collaborative efforts among people with kidney disease, their care partners, healthcare providers, and all involved stakeholders for elevating education and awareness on kidney health and saving lives with this disease.
     
    Conclusions
    In bridging the gap of knowledge to improve outcomes for those with kidney disease on a global basis, an in-depth understanding of the needs of the community is required. The same can be said for policy development, understanding the processes in place for engagement of governments worldwide, all underpinned by the important principle of codesign of resources and policy that meets the needs of the community for which it is intended.
     
    For WKD 2022, kidney organisations, including the International Society of Nephrology and International Federation of Kidney Foundations—World Kidney Alliance, have a responsibility to immediately work towards shifting the patient-deficit health literacy narrative to that of being the responsibility of clinicians and health policy makers. Low health literacy occurs in all countries regardless of income status; hence, simple, low-cost strategies are likely to be effective. Communication, universal precautions, and teach-back can be implemented by all members of the kidney healthcare team. Through this vision, kidney organisations will lead the shift to improved patient-centred care, support for care partners, health outcomes, and the global societal burden of kidney healthcare.
     
    Author contributions
    All authors contributed equally to the conception, preparation, and editing of the manuscript.
     
    Conflicts of interest
    K Kalantar-Zadeh reports honoraria from Abbott, Abbvie, ACI Clinical, Akebia, Alexion, Amgen, Ardelyx, AstraZeneca, Aveo, BBraun, Cara Therapeutics, Chugai, Cytokinetics, Daiichi, DaVita, Fresenius, Genentech, Haymarket Media, Hospira, Kabi, Keryx, Kissei, Novartis, Pfizer, Regulus, Relypsa, Resverlogix, Dr Schaer, Sandoz, Sanofi, Shire, Vifor, UpToDate, and ZS-Pharma. V Liakopoulos reports nonfinancial support from Genesis Pharma. G Saadi reports personal fees from Multicare, Novartis, Sandoz, and AstraZeneca. E Tantisattamo reports nonfinancial support from Natera. Other authors declared no competing interests.
     
    Funding/support
    This editorial received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
     
    Declaration
    This article was published in Kidney International (Langham RG, Kalantar-Zadeh K, Bonner A, et al. Kidney health for all: bridging the gap in kidney health education and literacy. Kidney International. 2022;101(3):432-440. https://doi. org/10.1016/j.kint.2021.12.017), and reprinted concurrently in several journals. The articles cover identical concepts and wording, but vary in minor stylistic and spelling changes, detail, and length of manuscript in keeping with each journal’s style. Any of these versions may be used in citing this article.
     
    References
    1. Centers for Disease Control and Prevention. Healthy people 2030: What is health literacy? Available from: https://www.cdc.gov/healthliteracy/learn/index.html. Accessed 16 Jan 2022.
    2. Nutbeam D. The evolving concept of health literacy. Soc Sci Med 2008;67:2072-8. Crossref
    3. Lloyd A, Bonner A, Dawson-Rose C. The health information practices of people living with chronic health conditions: implications for health literacy. J Librariansh Inf Sci 2014;46:207-16. Crossref
    4. Sørensen K, Van den Broucke S, Fullam J, et al. Health literacy and public health: a systematic review and integration of definitions and models. BMC Public Health 2012;12:80. Crossref
    5. Nutbeam D, Lloyd JE. Understanding and responding to health literacy as a social determinant of health. Annu Rev Public Health 2021;42:159-73. Crossref
    6. Shah JM, Ramsbotham J, Seib C, Muir R, Bonner A. A scoping review of the role of health literacy in chronic kidney disease self-management. J Ren Care 2021;47:221-33. Crossref
    7. Dinh HT, Nguyen NT, Bonner A. Healthcare systems and professionals are key to improving health literacy in chronic kidney disease. J Ren Care 2022;48:4-13. Crossref
    8. Dodson S, Good S, Osborne R. Health Literacy Toolkit for Low- and Middle-income Countries: a Series of Information Sheets to Empower Communities and Strengthen Health Systems. New Delhi: World Health Organization; 2015.
    9. Taylor DM, Fraser S, Dudley C, et al. Health literacy and patient outcomes in chronic kidney disease: a systematic review. Nephrol Dial Transplant 2018;33:1545-58. Crossref
    10. Taylor DM, Bradley JA, Bradley C, et al. Limited health literacy is associated with reduced access to kidney transplantation. Kidney Int 2019;95:1244-52. Crossref
    11. Brega AG, Barnard J, Mabachi NM, et al. AHRQ Health Literacy Universal Precautions Toolkit, Second Edition. (Prepared by Colorado Health Outcomes Program, University of Colorado Anschutz Medical Campus under Contract No. HHSA290200710008, TO#10.) AHRQ Publication No. 15-0023-EF. Rockville, MD: Agency for Healthcare Research and Quality; Jan 2015.
    12. Australian Commission on Safety and Quality in Health Care. Health literacy: taking action to improve safety and quality. Sydney: ACSQHC, 2014. Available from: https://www.safetyandquality.gov.au/publications-and-resources/resource-library/health-literacy-taking-action-improve-safety-and-quality. Accessed 17 Jan 2022.
    13. Visscher BB, Steunenberg B, Heijmans M, et al. Evidence on the effectiveness of health literacy interventions in the EU: a systematic review. BMC Public Health 2018;18:1414. Crossref
    14. Boonstra MD, Reijneveld SA, Foitzik EM, Westerhuis R, Navis G, de Winter AF. How to tackle health literacy problems in chronic kidney disease patients? A systematic review to identify promising intervention targets and strategies. Nephrol Dial Transplant 2020;36:1207-21. Crossref
    15. Nguyen NT, Douglas C, Bonner A. Effectiveness of selfmanagement programme in people with chronic kidney disease: a pragmatic randomized controlled trial. J Adv Nurs 2019;75:652-64. Crossref
    16. Synnot A, Bragge P, Lowe D, et al. Research priorities in health communication and participation: international survey of consumers and other stakeholders. BMJ Open 2018;8:e019481. Crossref
    17. Kalantar-Zadeh K, Li PK, Tantisattamo E, et al. Living well with kidney disease by patient and care-partner empowerment: kidney health for everyone everywhere. Kidney Int 2021;99:278-84. Crossref
    18. Jager KJ, Kovesdy C, Langham R, Rosenberg M, Jha V, Zoccali C. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Kidney Int 2019;96:1048-50. Crossref
    19. Li PK, Garcia-Garcia G, Lui SF, et al. Kidney health for everyone everywhere—from prevention to detection and equitable access to care. Kidney Int 2020;97:226-32. Crossref
    20. Gilford S. Patients helping patients: the Renal Support Network. Nephrol Nurs J 2007;34:76.
    21. Muhammad S, Allan M, Ali F, Bonacina M, Adams M. The renal patient support group: supporting patients with chronic kidney disease through social media. J Ren Care 2014;40:216-8. Crossref
    22. Li WY, Chiu FC, Zeng JK, et al. Mobile health app with social media to support self-management for patients with chronic kidney disease: prospective randomized controlled study. J Med Internet Res 2020;22:e19452. Crossref
    23. Pase C, Mathias AD, Garcia CD, Garcia Rodrigues C. Using social media for the promotion of education and consultation in adolescents who have undergone kidney transplant: protocol for a randomized control trial. JMIR Res Protoc 2018;7:e3. Crossref
    24. Kalantar-Zadeh K, Jafar T, Nitsch D, Neuen BL, Perkovic V. Chronic kidney disease. Lancet 2021;398:786-802. Crossref
    25. Chen L, Sivaparthipan CB, Rajendiran S. Unprofessional problems and potential healthcare risks in individuals’ social media use. Work 2021;68:945-53. Crossref
    26. Henderson ML, Herbst L, Love AD. Social media and kidney transplant donation in the United States: clinical and ethical considerations when seeking a living donor. Am J Kidney Dis 2020;76:583-5. Crossref
    27. Henderson ML. Social media in the identification of living kidney donors: platforms, tools, and strategies. Curr Transplant Rep 2018;5:19-26. Crossref
    28. Newton K, van Deth JW, editors. Foundations of Comparative Politics Democracies of the Modern World. 2nd ed. Cambridge, UK: Cambridge University Press; 2010. Crossref
    29. Anderson JE. Public Policymaking: An Introduction. 2nd ed. Boston, MA: Houghton Mifflin; 1994.
    30. Young E, Quinn L, eds. Writing effective public policy papers: a guide to policy advisers in Central and Eastern Europe. Budapest, Hungary: Open Society Institute. 2002. Available from: https://www.icpolicyadvocacy.org/sites/icpa/files/downloads/writing_effective_public_policy_papers_young_quinn.pdf. Accessed 13 Dec 2021.
    31. Young E, Quinn L, eds. Making research evidence matter: a guide to policy advocacy in transition countries. Budapest, Hungary: Open Society Foundations. 2012. Available from: https://advocacyguide.icpolicyadvocacy.org/sites/icpa-book.local/files/Policy_Advocacy_Guidebook_2012.pdf. Accessed 13 Dec 2021.
    32. Start D, Hovland I. Tools for policy impact: a handbook for researchers, research and policy in development programme. London, UK: Overseas Development Institute. 2004. Available from: https://www.ndi.org/sites/default/files/Tools-for-Policy-Impact-ENG.pdf. Accessed 13 Dec 2021.

    Leveraging the power of health communication: messaging matters not only in clinical practice but also in public health

    Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
     
    EDITORIAL
    Leveraging the power of health communication: messaging matters not only in clinical practice but also in public health
    Harry HX Wang, PhD1,2,3 #; YT Li, MPH4 #; Martin CS Wong, MD, MPH5,6
    1 School of Public Health, Sun Yat-Sen University, Guangzhou, China
    2 Department of General Practice, The Second Hospital of Hebei Medical University, Shijiazhuang, China
    3 Usher Institute, Deanery of Molecular, Genetic and Population Health Sciences, The University of Edinburgh, Scotland, United Kingdom
    4 State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou, China
    5 JC School of Public Health and Primary Care, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong
    6 Editor-in-Chief, Hong Kong Medical Journal
    # Equal contribution
     
    Corresponding author: Prof Martin CS Wong (wong_martin@cuhk.edu.hk)
     
     Full paper in PDF
     
    In routine clinical practice, communicating with patients in a clear and persuasive manner during patient-provider encounters is increasingly important for effective healthcare. This greatly helps in improving access to care and diagnostic safety, fostering continuous healing relationships, reducing medical errors, strengthening family and social support, enhancing care adherence, increasing patient satisfaction, and avoiding malpractice claims.1 2 3 Moreover, effective communication is a pivotal ingredient in patient engagement and shared decision-making across the care continuum from screening and diagnosis through palliative care built on the patient’s greater knowledge of health problems and the clinician’s better ability to recognise individual patient beliefs, values, needs, and preferences.4 This, in turn, enables the development and dissemination of evidence-based, personalised messages from clinicians to inform diagnosis, treatment options, prognosis, and the likelihood of severe adverse effects for achieving optimal care for patients.5
     
    The benefits of effective health communications in improving patient health outcomes and well-being also extend beyond clinical care. Whether to inform people about their health facts or to exert a long-lasting influence on their behaviour for living a healthier life, the use of different strategies is crucial in public health campaigns spanning a variety of areas, including the ongoing coronavirus disease 2019 (COVID-19) pandemic.6 7 Of equal importance is the integration of health communication in public advocacy and outbreak responses, which necessitate appropriate, practical, and straightforward messages that fill knowledge gaps for the target audience.
     
    From a public health perspective, eye health is a global imperative for achieving universal health coverage and many of the Sustainable Development Goals. Improving eye health contributes substantially to maintaining independence and daily life activities, improving quality of life and well-being, ensuring educational attainment and workplace productivity, and reducing poverty and inequalities.8 Similar to the prevention and management of most chronic diseases, promoting and improving eye health also require a life course approach that aims to minimise risk factors through evidence-based interventions at important life stages from as early as the perinatal period through early childhood to adolescence, and into older age. Therefore, school-based public health efforts that incorporate expertise of education and communication of health messages to facilitate long-term behaviour changes in children and adolescents would have the most impact on reducing disease risk factors and disease onset in later-life.9 Engagement in collaborative endeavours from both teachers and parents has been proven effective in the problem-solving process to support school-age children with developmental disorders and impairments in social interaction.10 Whether the school-family partnership underpinned by teacher-parent communication could be linked with improved behaviour changes, eg, vision screening attendance, in other specific disease contexts such as vision impairment warrants further investigation.
     
    Uncorrected refractive error, including myopia, hyperopia, astigmatism, and anisometropia, serve as the major and most easily avoidable cause of vision impairment among school-age children who are at risk of poor educational performance and social malfunctioning. In this issue of the Hong Kong Medical Journal, Du et al11 explore the association between teacher-parent communication and eye-health seeking behaviours of primary school students in a cross-sectional study conducted in rural China. The authors found that the delivery of a single clear message to parents from the teacher on the student’s inability to see the blackboard clearly could substantially improve the refractive examination attendance and spectacles wearing among students. It adds evidence to extend the benefits of teacher-parent communication beyond better educational experiences, coordinated learning environments, improved academic achievements, and enhanced habits development in daily life. The findings also provide impetus for further in-depth research to advance our understanding of the extent to which different modalities of teacher-parent interactions could inform, educate and empower parents about their child’s eye health issues. This may help in generating evidence for developing well-integrated, innovative strategies to plan and implement school-based eye health initiatives featured by strengthened partnership with teachers, parents, students, and the wider community to address undiagnosed or untreated refractive error and other vision impairment.
     
    At the global level, an earlier report from the World Health Organization in 2019 highlighted the considerable challenges of a continuum of eye care throughout people’s lives: over 2 billion people worldwide are visually impaired or blind, and nearly half of vision impairments could have been prevented or have yet to be addressed through cost-effective and feasible health interventions.12 The subsequent 74th World Health Assembly organised in April 2021 has endorsed the global targets for effective coverage of refractive errors and cataract surgery—the two leading causes of vision impairment and blindness. A 40% point increase in effective coverage of refractive error and a 30% point increase in effective coverage of cataract surgery is envisaged by 2030. Apart from refractive errors and cataract, there are a range of other common ophthalmic conditions that pose enormous threats to healthcare such as glaucoma and diabetic retinopathy, which can lead to eye vision loss if not detected and treated early. Most recently, the Resolution entitled ‘Vision for Everyone; accelerating action to achieve the Sustainable Development Goals’ has been adopted by the United Nations General Assembly in July 2021 to urge the implementation of integrated people-centred eye care in health systems across the wide spectrum of promotive, preventive, curative and rehabilitative services by 2030. The United Nations vision underscores the significance of raising awareness and engaging and empowering people and communities pertaining to eye care needs and the importance of vision for all. To achieve this goal, eye health education and promotion within the wider community needs to reduce barriers that impede the affective dimensions of message dissemination and to optimise knowledge communication and service uptake.
     
    However, achieving effective communication of health messages is never an easy task. Previous studies highlighted the increasing need for strengthening health communication and promotion in socially disadvantaged groups,13 or those living in deprived areas,14 and for care empowerment in managing underdiagnosed long-term conditions that require better professional education and tailored messages in primary care.15 16 The need for health communication efforts and mass media messages promoting infection control measures and use of guidelines in public education is also highlighted in risk communications and community engagement against the COVID-19 outbreak.17
     
    A growing body of evidence indicates that digital communication, eg, mobile messaging for telecommunications or social media platform characterised by multi-channel communications, may offer innovative means for sharing, disseminating and amplifying health messages across all aspects of the communication spectrum to target audience and communities with unique merits such as enhanced audio-visual capabilities, improved attendance at healthcare appointments, and increased uptake of comprehensive eye examinations.18 19
     
    The World Health Organization has also proposed a strategic framework that highlights the principles of accessible, relevant, actionable, timely, credible and trusted, and understandable communication.20 The framework could be used a basis for operationalising effective, integrated and coordinated communication across a broad range of health issues from chronic conditions (eg, vision impairment) to emerging risks (eg, COVID-19), and for measuring the impact of tailored communication efforts on health and well-being over time. A further step towards empirical evidence from well-designed studies on the impact of enhanced health communication with individuals and their families on disease prevention, health promotion, and quality of life through public health measures and its enablers would pave the way for achieving universal health coverage for individuals, communities, and society at large.
     
    Author contributions
    All authors contributed to the concept or design; acquisition of data; analysis or interpretation of data; drafting of the article; and critical revision for important intellectual content. All authors had full access to the data, contributed to the study, approved the final version for publication, and take responsibility for its accuracy and integrity.
     
    Conflicts of interest
    The authors have declared no conflict of interest.
     
    References
    1. Street RL Jr, Makoul G, Arora NK, Epstein RM. How does communication heal? Pathways linking clinician-patient communication to health outcomes. Patient Educ Couns 2009;74:295-301. Crossref
    2. van Dael J, Gillespie A, Neves AL, Darzi A. Patient–clinician communication research for 21st century health care. Br J Gen Pract 2022;72:52-3. Crossref
    3. Burgener AM. Enhancing communication to improve patient safety and to increase patient satisfaction. Health Care Manag (Frederick) 2020;39:128-32. Crossref
    4. Kaldjian LC. Concepts of health, ethics, and communication in shared decision making. Commun Med 2017;14:83-95. Crossref
    5. Vermeir P, Vandijck D, Degroote S, et al. Communication in healthcare: a narrative review of the literature and practical recommendations. Int J Clin Pract 2015;69:1257-67. Crossref
    6. Edwards DJ. Ensuring effective public health communication: insights and modeling efforts from theories of behavioral economics, heuristics, and behavioral analysis for decision making under risk. Front Psychol 2021;12:715159. Crossref
    7. Nan X, Iles IA, Yang B, Ma Z. Public health messaging during the COVID-19 pandemic and beyond: lessons from communication science. Health Commun 2022;37:1-19. Crossref
    8. Burton MJ, Ramke J, Marques AP, et al. The Lancet Global Health Commission on Global Eye Health: vision beyond 2020. Lancet Glob Health 2021;9:e489-551. Crossref
    9. Bay JL, Hipkins R, Siddiqi K, et al. School-based primary NCD risk reduction: education and public health perspectives. Health Promot Int 2017;32:369-79. Crossref
    10. Azad GF, Kim M, Marcus SC, Mandell DS, Sheridan SM. Parent-teacher communication about children with autism spectrum disorder: an examination of collaborative problem-solving. Psychol Sch 2016;53:1071-84. Crossref
    11. Du K, Huang J, Guan H, Zhao J, Zhang Y, Shi Y. Teacher-to-parent communication and vision care-seeking behaviour among primary school students. Hong Kong Med J 2022;28:152-60. Crossref
    12. World Health Organization. World Report on Vision. Geneva: World Health Organization; 2019.
    13. Hon KL, Leung KK. Healthcare and health promotion for the sub-health state Hong Kong population. Hong Kong Med J 2021;27:73. Crossref
    14. Zhou Q, An Q, Wang N, et al. Communication skills of providers at primary healthcare facilities in rural China. Hong Kong Med J 2020;26:208-15. Crossref
    15. Lam K, Chan WS, Luk JK, Leung AY. Assessment and diagnosis of dementia: a review for primary healthcare professionals. Hong Kong Med J 2019;25:473-82. Crossref
    16. Kalantar-Zadeh K, Li PK, Tantisattamo E, et al. Living well with kidney disease by patient and care partner empowerment: kidney health for everyone everywhere. Hong Kong Med J 2021;27:97-8. Crossref
    17. Yu EY, Leung WL, Wong SY, Liu KS, Wan EY; HKCFP Executive and Research Committee. How are family doctors serving the Hong Kong community during the COVID-19 outbreak? A survey of HKCFP members. Hong Kong Med J 2020;26:176-83. Crossref
    18. Atta S, Omar M, Kaleem SZ, Waxman EL. The use of mobile messaging for telecommunications with patients in ophthalmology: a systematic review. Telemed J E Health 2022;28:125-37. Crossref
    19. Maitra C, Rowley J. Delivering eye health education to deprived communities in India through a social media-based innovation. Health Info Libr J 2021;38:139-42. Crossref
    20. World Health Organization. Strategic Communications Framework for WHO in the Western Pacific Region. Manila: WHO Regional Office for the Western Pacific; 2017.

    Breast cancer screening—towards a broader coverage of the general population

    Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
     
    EDITORIAL
    Breast cancer screening—towards a broader coverage of the general population
    CY Lui, FHKCR, FHKAM (Radiology)1; Julian CY Fong, FHKCR, FHKAM (Radiology)1; Martin CS Wong, MD, MPH2,3
    1 Hong Kong Women’s Imaging Limited, Hong Kong
    2 Jockey Club School of Public Health and Primary Care, The Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong
    3 Editor-in-Chief, Hong Kong Medical Journal
     
    Corresponding author: Dr CY Lui (cylui@hkwi.com.hk)
     
     Full paper in PDF
     
    The primary purpose of breast cancer screening is to detect breast cancer earlier at an asymptomatic stage hopefully before it becomes more advanced or metastasised, which is the major cause of patient death. The breast cancer detected under screening are usually smaller in size with better prognosis,1 2 and patients can therefore benefit from less extensive surgical treatment with fewer complications such as lymphoedema. It may also reduce morbidity secondary to the use of systematic chemotherapy, and lower its recurrence rate
     
    In 2021, the Cancer Expert Working Group on Cancer Prevention and Screening (CEWG) updated its recommendations on breast cancer screening for the female general population of Hong Kong. Women with certain combinations of risk factors are recommended to consider mammography screening every 2 years.3 Addressing the rising breast cancer incidence in Hong Kong, the updated recommendation is a big leap forward compared to the previous version which only mentioned ‘insufficient scientific evidence to recommend or against mammography screening’.
     
    The benefits of mammography have been widely reported in Western populations.4 However, whether studies from Western populations are directly applicable in Chinese populations remains controversial, primarily because this population generally has denser breast tissue and difference in incidence. In this respect, a 10-year study conducted in Taiwan, involving over 1.4 million women of mainly Chinese ethnicity, found that universal biennial mammography was associated with reduction of mortality by 41% and stage II+ breast cancer by 30%, compared with annual clinical breast examination.5 In Hong Kong, Lui et al6 found that the crude cancer detection rate of an opportunistic screening programme was five per 1000 mammograms performed. Experience from Hong Kong Breast Cancer Foundation found a detection rate of 7.5 per 1000 asymptomatic women screened.7 These data suggested that mammography screening is useful to detect breast cancers in Hong Kong.
     
    Potential risks of breast screening have also been overstated, including overdiagnosis and overtreatment of ductal carcinoma in situ (DCIS) detected by mammography screening. However, Duffy et al8 studied over 5 million women screened in the United Kingdom for four consecutive yearly screening rounds, and showed that there was a significant negative association between detection of DCIS at screening and invasive interval cancers. For every three screen-detected DCIS, there was one less invasive interval cancer over the next 3 years. These results indicate that early detection of DCIS and subsequent treatment is worthwhile in prevention of future invasive diseases.
     
    Another risk that is often overstated is the effect of screening causing anxiety among patients. Anxiety in patients who received breast cancer screening tends to be short-term, and these women have a high tolerance for false positive results.9 10 11 Findings from the longitudinal DMIST (Digital Mammographic Imaging Screening Trial) showed that the anxiety associated with false positive mammogram was only transient with no measurable health utility decrement, yet it increased women’s intention to undergo future breast cancer screening.12 Although there is potential for false positive results to cause anxiety and lead to unnecessary biopsy and treatment, the situation can be much alleviated with updated technology and quality assurance by experts with adequate experience in breast screening.
     
    Bilateral two-view full-field digital mammography is currently the standard of screening mammography. With technological advancements, digital breast tomosynthesis (DBT), also known as 3D mammogram, has become more widely used. Friedewald et al13 found that DBT was associated with a 41% increase in invasive cancer detection, 49% increase in positive predictive value for recall, 21% increase in positive predictive value for biopsy, and 15% reduction of overall number of recalls.
     
    Older studies reported that the radiation dose of DBT was much higher than that of conventional two-dimensional (2D) digital mammography. However, these studies often compared the radiation dose between “DBT combined with digital mammography” and “digital mammography only”. Using newer DBT technology with synthesised 2D mammogram capacity without separate scanning for 2D images, the radiation dose of DBT is comparable to that of conventional 2D digital mammography—and just less than half of the United States Food and Drug Administration Mammography Quality Standards Act dose limit for mammography.14 And with the use of DBT, it is associated with fewer additional radiation exposure from recall for additional cone compression view. This newer DBT technology is now widely available in Hong Kong.
     
    To implement a successful breast cancer screening programme in Hong Kong, modern hardware and manpower readiness are equally important. The imaging centre should have mammography machines, radiographers, and radiologists that meet the standards recommended by Hong Kong College of Radiologists.15 Quality assurance, including regular auditing of the programme’s performance should be in place. Multidisciplinary meetings with radiologists, surgeons, pathologists, and oncologists working in as a team should be held regularly to discuss relevant cases and to facilitate further investigations or treatment plans. There should also be administrative support to follow up on screening and biopsy results, and provide timely arrangement of further investigation or treatment if cancer is suspected or confirmed. A system should be implemented to remind patients to attend the next screening appointment.
     
    To prepare for large-scale breast cancer screening, forward planning is essential, such as training of an adequate number of mammographers, radiologists with a special interest in breast screening, and breast surgeons specialised in early breast cancer surgery and treatment.
     
    Whereas the risks of screening are frequently discussed, the harms of not screening are often overlooked. Those women not attending screening are associated with development of a significantly larger tumour, a more advanced stage of disease at diagnosis, poorer prognosis, lower survival rate, and higher recurrence rate. There is also a higher cost and extent of treatment, especially if there is a need for chemotherapy for advanced disease. It has been estimated that the cost of treating advanced metastatic breast cancer exceeds US$250 000 per patient, and the average cost of treating advanced cancer in the first year after diagnosis is almost double that of early cancers.16 In addition to the cost for treatment, there are extra societal costs, including productivity loss and staff turnover, as well as the time and expenses of the caretakers of the patients.
     
    The relatively dense breast tissue among Chinese women not only impairs the performance and resulting benefits of mammography, but also is an independent risk factor for breast cancer. The technology of DBT, supplemented by ultrasound or magnetic resonance imaging (MRI), may be used to enhance the sensitivity for detecting cancer. Whereas supplementary ultrasound is widely used because of its easy availability, a recent study found that contrast enhanced MRI provides the greatest increase in cancer detection and reduce interval cancers and late-stage disease.17 The abbreviated MRI technique will reduce the cost and improve the availability of this technology. It is hoped that the CEWG may take this newer evidence into consideration in its next update.
     
    With the updated recommendation of CEWG on risk-based screening, and the experience of opportunistic mammography screening in Hong Kong since 1993,6 we believe that Hong Kong should have the capability and expertise to organise quality, population-based screening similar to other Asian countries and cities. Because breast screening is a primary care activity, we anticipate that district health centres may play a crucial role to enhance awareness and promote its implementation in the community as one of their key roles and functions. We are confident that the findings from evaluation of the Breast Cancer Screening Pilot Programme started on 6 September 2021 could further inform policy formulation.
     
    Author contributions
    All authors contributed to the editorial, approved the final version for publication, and take responsibility for its accuracy and integrity.
     
    Conflicts of interest
    The authors have declared no conflict of interest.
     
    References
    1. Tabar L, Tot T, Dean PB. Breast Cancer—The Art and Science of Early Detection with Mammography: Perception, Interpretation, Histopathologic Correlation. Germany: Thieme; 2004: 174-7.
    2. Tabár L, Duffy SW, Vitak B, Chen HH, Prevost TC. The natural history of breast carcinoma: what have we learned from screening? Cancer 1999;86:449-62. Crossref
    3. Cancer Expert Working Group on Cancer Prevention and Screening (August 2018 to July 2021); Tsang TH, Wong KH, Allen K, et al. Update on the Recommendations on Breast Cancer Screening by the Cancer Expert Working Group on Cancer Prevention and Screening. Hong Kong Med J 2022;28:161-8.
    4. Sitt JC, Lui CY, Sinn LH, Fong JC. Understanding breast cancer screening—past, present, and future. Hong Kong Med J 2018;24:166-74. Crossref
    5. Yen AM, Tsau HS, Fann JC, et al. Population-based breast cancer screening with risk-based and universal mammography screening compared with clinical breast examination: a propensity score analysis of 1 429 890 Taiwanese women. JAMA Oncol 2016;2:915-21. Crossref
    6. Lui CY, Lam HS, Chan LK, et al. Opportunistic breast cancer screening in Hong Kong; a revisit of the Kwong Wah Hospital experience. Hong Kong Med J 2007;13:106-13.
    7. Hong Kong Breast Cancer Foundation. Fact Sheet (last updated on 1 April 2021). Available from: https://www.hkbcf.org/en/about_us/main/upload/category/442/self/6080f662635ff.pdf. Accessed 20 Mar 2022.
    8. Duffy SW, Dibden A, Michalopoulos D, et al. Screen detection of ductal carcinoma in situ and subsequent incidence of invasive interval breast cancers: a retrospective population-based study. Lancet Oncol 2016;17:109-14. Crossref
    9. Lowe JB, Balanda KP, Del Mar C, Hawes E. Psychologic distress in women with abnormal findings in mass mammography screening. Cancer 1999;85:1114-8. Crossref
    10. Ekeberg Ø, Skjauff H, Kåresen R. Screening for breast cancer is associated with a low degree of psychological distress. Breast 2001;10:20-4. Crossref
    11. Schwartz LM, Woloshin S, Sox HC, Fischhoff B, Welch HG. US women’s attitudes to false positive mammography results and detection of ductal carcinoma in situ: cross sectional survey. BMJ 2000;320:1635-40. Crossref
    12. Tosteson AN, Fryback DG, Hammond CS, et al. Consequences of false-positive screening mammograms. JAMA Intern Med 2014;174:954-61. Crossref
    13. Friedewald SM, Rafferty EA, Rose SL, et al. Breast cancer screening using tomosynthesis in combination with digital mammography. JAMA 2014;311:2499-507. Crossref
    14. Skaane P, Bandos AI, Eben EB, et al. Two-view digital breast tomosynthesis screening with synthetically reconstructed projection images: comparison with digital breast tomosynthesis with full-field digital mammographic images. Radiology 2014;271:655-63. Crossref
    15. Mammography Statement. Revised version 2015. Hong Kong College of Radiologists. Available from: https://www.hkcr.org/templates/OS03C00336/case/lop/HKCR%20Mammography%20Statement_rev20150825.pdf. Accessed 20 Mar 2022.
    16. Montero AJ, Eapen S, Gorin B, Adler P. The economic burden of metastatic breast cancer: a U.S. managed care perspective. Breast Cancer Res Treat 2012;134:815-22. Crossref
    17. Berg WA, Rafferty EA, Friedewald SM, Hruska CB, Rahbar H. Screening algorithms in dense breasts: AJR Expert Panel Narrative Review. AJR Am J Roentgenol 2021;216:275-94. Crossref

    Expert witnesses and areas of expertise

    Hong Kong Med J 2022 Feb;28(1):4–5  |  Epub 14 Feb 2022
    © Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
     
    EDITORIAL
    Expert witnesses and areas of expertise
    James SP Chiu, FHKAM (Surgery), LLB (Hons) Lond; Gilberto KK Leung, FHKAM (Surgery), LLM
    Professionalism and Ethics Committee, Hong Kong Academy of Medicine
     
    Corresponding author: Dr James SP Chiu (drjameschiu@yahoo.com.hk)
     
     Full paper in PDF
     
     
    Expert witnesses play important roles in medicolegal and disciplinary proceedings through the provision of opinions that are within their respective areas of expertise. Contentions may occasionally arise concerning the expertise of an individual witness and whether the scope of his expertise has been exceeded in certain situations.
     
    Defining specialists and experts
    The terms “specialist” and “expert” are often used interchangeably but they may carry different meanings in the case of professionals. In 1998, the Medical Council of Hong Kong established a Specialist Register to provide for specialist registration of medical practitioners who have been awarded Fellowships of the Hong Kong Academy of Medicine or who have achieved a comparable professional standard and have applied to the Medical Council of Hong Kong for specialist registration.1 By contrast, there is no official list of medical experts in Hong Kong and the term “expert” is not defined in Cap. 1 Interpretation and General Clauses Ordinance or Cap. 4A The Rules of the High Court. The Hong Kong Academy of Medicine maintains a list of Academy Fellows who are willing to serve as expert witnesses in their respective specialties. However, disputing parties and their legal advisers may freely engage any registered doctor or dentist of their choice to be their expert witness, whether the individual is on the Academy’s list or not.
     
    Duties and responsibilities of expert witnesses in relation to their expertise
    In the landmark case of The Ikarian Reefer,2 the court set out the duties and responsibilities of expert witnesses in civil cases, two of which are related to expertise. First, an expert witness should provide independent assistance to the Court by way of objective unbiased opinion in relation to matters within his expertise. Second, an expert witness should make it clear when a particular question or issue falls outside his expertise. Similarly, the Code of Conduct for Expert Witnesses3 provides that an expert witness has an overriding duty to help the Court impartially and independently on matters relevant to the expert’s area of expertise. A report by an expert witness must (in the body of the report or in an annexure) specify, if applicable, that a particular question or issue falls outside his field of expertise. In Zahid Anwar v Graceful Sound Limited,4 Bharwaney J stated that, “Experts are instructed to assist the court by offering their expert opinion on areas which are within their specialist experience and which are not matters of common knowledge”.
     
    Matters relating to an expert witness’ areas of expertise
    Medicine has evolved to include many specialties under which there are multiple subspecialties. Professional expertise is accumulated from years of studying, training, and personal experience in a specific area of medicine. It follows that not all specialists are competent expert witnesses. A specialist in Gastroenterology and Hepatology may not act as an expert witness for a case concerning endoscopic retrograde cholangiopancreatography, sphincterotomy, and extraction of common bile duct stones if he does not have substantial knowledge and practical experience in these procedures.
     
    In a recent Hong Kong case, the expert witness for the defendants was a specialist in paediatrics, and that for the plaintiffs was a specialist in paediatric surgery. The court acknowledged that the relevant standard to be applied under the Bolam test on the issue of liability for medical negligence was whether the defendant (who was a paediatrician) had acted in accordance with the practice accepted as proper by a responsible body of “medical men skilled in that particular art”, which particular art was that of paediatric specialists and not that of paediatric surgery specialists.5 The boundary becomes less clear when a specialist in general surgery is asked to comment on an orthopaedic case. It may be proper for him to comment on general principles of postoperative care but not detailed surgical techniques in orthopaedics. The situation is even more challenging when the case involves several body systems and multidisciplinary care. Medical and dental practitioners invited to be expert witnesses should be mindful of any limitations of their areas of expertise in relation to the medicolegal issue at hand and to act within those boundaries as a matter of duty to the court and professional respect towards their peers who possess the relevant specialised skills and knowledge. In cases involving matters of multiple areas of expertise, the practitioner may suggest the parties to invite suitable experts of other specialties or subspecialties to be witnesses, if necessary.
     
    Medical and dental practitioners appointed to give evidence in courts, tribunals, or inquests are advised to: consider seeking legal advice; provide answers truthfully based on their personal knowledge and beliefs; avoid making up answers; avoid answering questions that are beyond their scope of practice; and exercise the right to refuse to answer questions that could result in self-incrimination.6
     
    Potential consequences of giving mistaken evidence
    Misleading or “manifestly wrong” expert evidence can have untoward and far-reaching consequences. The professional or academic status of an expert witness by itself offers no excuses. In the United Kingdom case of R v Sally Clark,7 a prosecution expert witness was Professor Sir Roy Meadow, an Emeritus Professor of Paediatrics and Child Health. Evidence relating to statistics were given by the professor, who did not disclose his lack of expertise in statistics. Mrs Clark was convicted of the murder of her two sons and received two life sentences in 1999. Her appeal was dismissed. It later transpired that Professor Meadow made one mistake, which was to misunderstand and misinterpret the statistics. Mrs Clark made a second appeal and was set free in 2003. Her father then made a complaint to the General Medical Council (GMC) alleging serious professional misconduct on the part of Professor Meadow. In 2005, the GMC found him guilty, and his name was erased from the register. He appealed to the High Court and the order of the GMC was quashed. The GMC appealed to the Court of Appeal in 2006.8 There were two distinct parts of the appeal. The first was whether an expert witness should be entitled to immunity from disciplinary, regulatory or fitness to practise proceedings in relation to statements made or evidence given by him in or for the purpose of legal proceedings. The second entailed a consideration of the GMC’s challenge to the High Court judge’s decision that Professor Meadow was not guilty of serious professional misconduct. The Court of Appeal allowed the first part of the appeal and held that the Fitness to Practice Panel of the GMC had jurisdiction to entertain the allegations against Professor Meadow. However, the second part of GMC's appeal on the issue of 'serious professional misconduct' was rejected.
     
    Training for expert witnesses
    Specialists do not automatically make good expert witnesses. It is advisable for anyone interested to take up this job to undergo formal training first. Start with simple cases and work closely with instructing lawyers to gain experience and accumulate the necessary skills. Otherwise, it can result in unpleasant experience if he has to appear in courts or tribunals and may even become a defendant himself or cause irreversible harm to the parties.
     
    Author contributions
    Both authors contributed to the editorial, approved the final version for publication, and take responsibility for its accuracy and integrity.
     
    Conflicts of interest
    The authors have declared no conflict of interest.
     
    References
    1. The Medical Council of Hong Kong. Available from: https://www.mchk.org.hk/english/registration/specialist_registration.html. Accessed 25 Nov 2021.
    2. The Ikarian Reefer [1993] Lloyd’s Rep 68, pp 81-82.
    3. Cap. 4A, The Rules of the High Court, Appendix D.
    4. Zahid Anwar v Graceful Sound Limited & Ors HCPI 410/2008 & HCPI 370/2009
    5. Sun Ming Lok v Choy Wing Ho & St Teresa’s Hospital HCPI 200/2017
    6. Tsang C, Lee V. Coroner’s inquest—What do you need to know? Hong Kong Medical Association News, October 2021: 23.
    7. R v Sally Clark [2003] EWCA Crim 1020
    8. GMC v Professor Sir Roy Meadow [2006] EWCA Civ 1390

    Why is a special section “Healthcare in Mainland China” so crucial for HKMJ?

    © Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
     
    EDITORIAL
    Why is a special section “Healthcare in Mainland China” so crucial for HKMJ?
    Jingchun Nie, PhD1; Yaojiang Shi, PhD1,2; Hao Xue, PhD1,2
    1 Center for Experimental Education in Economics (CEEE), Shaanxi Normal University, Xi’an, Shaanxi, China
    2 Section Editor, ‘Healthcare in Mainland China’, Hong Kong Medical Journal
     
    Corresponding author: Dr Hao Xue (xuehjjx@gmail.com)
     
     Full paper in PDF
     
    In order to promote high-quality research from mainland China among medical professionals in Hong Kong, the Hong Kong Medical Journal (HKMJ) Editorial Board launched a Special Section titled “Healthcare in Mainland China” in June 2021.1 We hope that studies from mainland China in this special section can speak to and shed light on healthcare in other developing countries and regions, and provide insight into Chinese healthcare practice for HKMJ’s international readers.
     
    For the past 2 years, coronavirus disease 2019 (COVID-19) has exerted a heavy burden on public health worldwide, and there is an increasing body of evidence reporting various effects and impacts of COVID-19. However, few studies have provided epidemiological and clinical characteristics of patients affected at the early stage of the COVID-19 outbreak.
     
    In this current issue of HKMJ under the “Healthcare in Mainland China” section, Gao et al2 report a retrospective study that included laboratory-confirmed 96 cases of COVID-19 in a hospital in Hangzhou City from 15 January 2020 to 30 March 2020. The authors investigated epidemiological, demographic, clinical, radiological, and laboratory features involving these cases; and found that, during the early stage of the COVID-19 outbreak, half of the patients were part of familial clusters. Therefore, they suggested that strict prevention and control measures during self-isolation should be implemented. They also found that patients aged >60 years with underlying co-morbidities were prone to lymphocytopenia and severe infection.
     
    China is the world’s most populous country, and the large population presents numerous healthcare issues. For example, China accounted for 24% of newly diagnosed cases and 30% of cancer-related deaths worldwide in 2020.3 There were also an estimated 93.8 million prevalent cases of cardiovascular diseases overall during 2016 in China, accounting for about 17.8% of the global burden.4 5 Moreover, nearly half of all vision problems among children globally occur in China.6 To address such a volume of challenges, China’s total healthcare expenditure was >7.2 trillion yuan in 2020, with >1.0 million clinics and hospitals, and >13.5 million medical personnel.7 In addition, there is a significant income disparity between urban and rural areas and between coastal and inland regions in mainland China. All of these factors lead to a broad and diverse wealth of healthcare research in the region.
     
    We highly appreciate and sincerely welcome more researchers and healthcare professionals to submit their research on healthcare in mainland China for consideration for publication in HKMJ. The HKMJ review process is highly selective, and only the highest quality submissions are accepted for publication. We hope to promote global healthcare improvement by providing our valued international and local readers with high-quality research from mainland China.
     
    Author contributions
    All authors contributed to the editorial, approved the final version for publication, and take responsibility for its accuracy and integrity.
     
    Conflicts of interest
    The authors have declared no conflict of interest.
     
    References
    1. Shi YJ, Xue H, Wong MCS. Call for papers: special section “Healthcare in Mainland China”. Hong Kong Med J 2021;27:174. Crossref
    2. Gao J, Zhang S, Zhou K, Liu J, Pu Z. Epidemiological and clinical characteristics of patients with COVID-19 from a designated hospital in Hangzhou City: a retrospective observational study. Hong Kong Med J 2022;28:54-63. Crossref
    3. Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl) 2021;134:783-91. Crossref
    4. Li X, Wu C, Lu J, et al. Cardiovascular risk factors in China: a nationwide population-based cohort study. Lancet Public Health 2020;5:e672-81. Crossref
    5. Liu S, Li Y, Zeng X, et al. Burden of cardiovascular diseases in China, 1990-2016: findings from the 2016 Global Burden of Disease Study. JAMA Cardiol 2019;4:342-52. Crossref
    6. Resnikoff S, Pascolini D, Mariotti SP, Pokharel GP. Global magnitude of visual impairment caused by uncorrected refractive errors in 2004. Bull World Health Organ 2008;86:63-70. Crossref
    7. Wang L, Chen Y. Determinants of China’s health expenditure growth: based on Baumol’s cost disease theory. Int J Equity Health 2021;20:213. Crossref

    Combating antimicrobial resistance during the COVID-19 pandemic

    Hong Kong Med J 2021 Dec;27(6):396–8  |  Epub 17 Nov 2021
    © Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
     
    EDITORIAL
    Combating antimicrobial resistance during the COVID-19 pandemic
    Edmond SK Ma, FHKAM (Community Medicine)1,2; KH Kung, MMedSc, FHKAM (Community Medicine)2; Hong Chen, MPH, FHKAM (Community Medicine)2
    1 Epidemiology Adviser, Hong Kong Medical Journal
    2 Infection Control Branch, Centre for Health Protection, Department of Health, Hong Kong SAR Government, Hong Kong
     
    Corresponding author: Dr Edmond SK Ma (edmond_sk_ma@dh.gov.hk)
     
     Full paper in PDF
     
     
    Global attention has been drawn to combat coronavirus disease 2019 (COVID-19), draining tremendous government resources, political commitment, public health measures, manpower of healthcare professionals, media, and public interest. The COVID-19 has also seriously affected the global effort against antimicrobial resistance (AMR). According to a survey conducted in late 2020 by the World Health Organization (WHO) AMR Surveillance and Quality Assessment Collaborating Centres Network, 63% (35 out of 56 countries) reported an increase in total prescriptions of antibiotics, with 47% (23/49), 57% (27/47), and 40% (18/45) of countries reporting increased use of WHO Access, Watch, and Reserve antibiotics, respectively.1 More importantly, 37% (13/35) and 40% (12/30) of countries reported an increase in multidrug-resistant organism (MDRO) healthcare-associated infections and MDRO infections in long-term care facilities, respectively. Outbreaks and increases in AMR acquisition, such as carbapenemase-producing Enterobacteriaceae, have also been reported by hospitals during the COVID-19 pandemic.2 3 4
     
    The situation of MDRO in Hong Kong is worrisome. The Hospital Authority has reported a higher rate of methicillin-resistant Staphylococcus aureus bacteraemia detected after 48 hours of admission in 2020 and the first half of 2021, compared with that of previous years, although this may be due to a reduction in hospital admission of milder cases.5 An outbreak of Candida auris, an often highly resistant emerging infection, during the third wave of the COVID-19 pandemic is also concerning. From 29 June 2020 to 9 October 2020, the Hospital Authority reported 41 patients with Candida auris colonisation to the Infection Control Branch of the Centre for Health Protection for infection control advice after discharge to residential care homes.6 The number of cases of carbapenem-resistant Enterobacteriaceae discharged to residential care homes for the elderly rose from 242 cases in 2019 to 259 cases in 2020, and then sharply to 329 cases between January and August 2021.
     
    The COVID-19 pandemic has affected antimicrobial stewardship activities and driven AMR in various ways. Drifting of resources, including laboratory capacity, reduced reagents and consumables, physician and nursing manpower, and public health staff, have undermined antimicrobial stewardship programmes in many countries. Weakened infection control due to fatigue and heavy workload of healthcare workers, and shortages of personal protective equipment in the early days of the pandemic further aggravated the problem. Hospital admission may increase the risk of healthcare-associated infections and the transmission of MDROs, which in turn may lead to increased antimicrobial use. Disruption to routine immunisation activities, due to COVID-19-related measures, has led to reductions in overall vaccination coverage globally, potentially leading to an overuse of antimicrobials.7 8 9 Low-level exposure to biocidal agents can strengthen drug-resistant strains and enhance the risk of cross resistance to antibiotics, particularly those that treat Gram-negative bacteria.10
     
    Another important impact of COVID-19 on increasing AMR is secondary bacterial infection among patients with COVID-19. Empirical treatment of patients with COVID-19 using antibiotics is common. A meta-analysis involving 154 studies and over 30 000 patients revealed that 74.6% of patients with COVID-19 received antibiotics, significantly higher than the estimated prevalence of bacterial co-infection.11 This is echoed by another review of studies published on hospitalised patients with COVID-19, which revealed 72% (1450/2010) of patients received antibiotics but only 8% (62/806) had bacterial or fungal co-infections.12 The most common type of secondary infection of COVID-19 was pneumonia (especially ventilator-associated pneumonia), followed by bloodstream and urinary tract infections, and the most commonly used agents included fluoroquinolones, cephalosporins, carbapenems, azithromycin, vancomycin, and linezolid.13 14 Those with complications of COVID-19 may require mechanical ventilation or other invasive devices, which increases the risk of acquiring hospital-associated pathogens that are often highly resistant, such as methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa, and Acinetobacter baumannii.15
     
    Despite the challenges posed to AMR, the COVID-19 pandemic also creates some opportunities, such as enhanced infection control measures among healthcare workers and the high alertness of personal hygiene among the general public. These measures, which include cough etiquette, hand hygiene, wearing of masks, and social distancing, have helped to reduce various infections, in particular those caused by respiratory pathogens.16 17 18 In addition, increased fear of attending healthcare facilities and postponement of elective hospital procedures have resulted in fewer medical consultations and antibiotic prescriptions. Surveillance data on wholesale antimicrobial consumption in Hong Kong show a substantial reduction (28.3%) in daily defined doses of antimicrobials from 19.02 million in 2019 to 13.63 million in 2020. In particular, there were major reductions (of between 35.3% and 51.5%) in wholesale supply to general practitioners of amoxicillin with or without beta-lactamase inhibitor, azithromycin, and cefuroxime, which are commonly prescribed to manage upper and lower respiratory tract infections. In Hong Kong, social distancing measures imposed by public health authorities, school and kindergarten closures, work-from-home policies, other restrictions involving catering businesses and scheduled premises such as fitness centres, beauty salons, karaoke establishments and sport centres, have all helped limit transmission through the respiratory route and person-to-person contact of not only COVID-19 but also other infections. Enhanced environmental hygiene using diluted household bleach containing 5.25% sodium hypochlorite can kill severe acute respiratory syndrome coronavirus 2 and other pathogens including MDROs.
     
    Although more research is needed to dissect the intermingled relationship between COVID-19 and AMR, it is of utmost importance to maintain efforts against AMR. The theme for World Antibiotic Awareness Week, held on 18 to 24 November 2021, was “Spread Awareness, Stop Resistance”. The dedicated page on the Centre for Health Protection website (https://www.chp.gov.hk/en/features/47850. html) includes access to the latest IMPACT (Interhospital Multi-disciplinary Programme on Antimicrobial ChemoTherapy) guideline, an evidence-based clinical guideline to ensure that patients receive the right antibiotic, at the right dose, at the right time, and for the right duration that leads to the best clinical outcome for the treatment or prevention of infection while producing low risk for subsequent resistance. The website also allows access to patient education and publicity materials on AMR. Similar to COVID-19, AMR is a complex global priority and everyone has a role to play.
     
    Author contributions
    All authors contributed to the editorial, approved the final version for publication, and take responsibility for its accuracy and integrity.
     
    Conflicts of interest
    The authors have declared no conflict of interest.
     
    Funding/support
    This study received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
     
    References
    1. Tomczyk S, Taylor A, Brown A, et al. Impact of the COVID-19 pandemic on the surveillance, prevention and control of antimicrobial resistance: a global survey. J Antimicrob Chemother 2021;76:3045-58. Crossref
    2. Tiri B, Sensi E, Marsiliani V, et al. Antimicrobial Stewardship Program, COVID-19, and infection control: spread of carbapenem-resistant Klebsiella pneumoniae colonization in ICU COVID-19 patients. What did not work? J Clin Med 2020;9:2744. Crossref
    3. Farfour E, Lecuru M, Dortet L, et al. Carbapenemase-producing Enterobacterales outbreak: another dark side of COVID-19. Am J Infect Control 2020;48:1533-6. Crossref
    4. Gomez-Simmonds A, Annavajhala MK, McConville TH, et al. Carbapenemase-producing Enterobacterales causing secondary infections during the COVID-19 crisis at a New York City hospital. J Antimicrob Chemother 2021;76:380-4. Crossref
    5. Hospital Authority, Hong Kong SAR Government. MRSA bacteremia in HA Hospitals—2021-Q1 & 2021-Q2. Available from: https://www.ha.org.hk/haho/ho/cico/MRSA_Bacteremia_in_HA_hospitals_2021Q1_2021Q2.pdf. Accessed 12 Sep 2021.
    6. Centre for Health Protection, Department of Health, Hong Kong SAR Government. Letter to doctor: alert on the rise in Candida auris colonisation in Hong Kong. Available from: https://www.chp.gov.hk/files/pdf/lti_c_auris_20201015_eng.pdf. Accessed 12 Sep 2021.
    7. Bramer CA, Kimmins LM, Swanson R, et al. Decline in child vaccination coverage during the COVID-19 pandemic—Michigan Care Improvement Registry, May 2016-May 2020. MMWR Morb Mortal Wkly Rep 2020;69:630-1. Crossref
    8. McDonald HI, Tessier E, White JM, et al. Early impact of the coronavirus disease (COVID-19) pandemic and physical distancing measures on routine childhood vaccinations in England, January to April 2020. Euro Surveill 2020;25:2000848. Crossref
    9. Saxena S, Skirrow H, Bedford H. Routine vaccination during covid-19 pandemic response. BMJ 2020;369:m2392. Erratum in: BMJ 2020;369:m2435. Crossref
    10. Getahun H, Smith I, Trivedi K, Paulin S, Balkhy HH. Tackling antimicrobial resistance in the COVID-19 pandemic. Bull World Health Organ 2020;98:442-442A. Crossref
    11. Langford BJ, So M, Raybardhan S, et al. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. Clin Microbiol Infect 2021;27:520-31. Crossref
    12. Rawson TM, Moore LS, Zhu N, et al. Bacterial and fungal coinfection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis 2020;71:2459-68.
    13. Clancy CJ, Buehrle DJ, Nguyen MH. PRO: The COVID-19 pandemic will result in increased antimicrobial resistance rates. JAC Antimicrob Resist 2020;2:dlaa049. Crossref
    14. Clancy CJ, Nguyen MH. Coronavirus disease 2019, superinfections, and antimicrobial development: what can we expect? Clin Infect Dis 2020;71:2736-43. Crossref
    15. Knight GM, Glover RE, McQuaid CF, et al. Antimicrobial resistance and COVID-19: intersections and implications. Elife 2021;10:e64139. Crossref
    16. Wan WY, Thoon KC, Loo LH, et al. Trends in respiratory virus infections during the COVID-19 pandemic in Singapore, 2020. JAMA Netw Open 2021;4:e2115973. Crossref
    17. Park KY, Seo S, Han J, Park JY. Respiratory virus surveillance in Canada during the COVID-19 pandemic: an epidemiological analysis of the effectiveness of pandemic-related public health measures in reducing seasonal respiratory viruses test positivity. PLoS One 2021;16:e0253451. Crossref
    18. Tanislav C, Kostev K. Fewer non-COVID-19 respiratory tract infections and gastrointestinal infections during the COVID-19 pandemic. J Med Virol 2021 Sep 7. Epub ahead of print. Crossref

    Airborne transmission of SARS-CoV-2: ventilation improvement strategies in preparation for school re-opening

    Hong Kong Med J 2021 Oct;27(5):328–9  |  Epub 30 Aug 2021
    © Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
     
    EDITORIAL
    Airborne transmission of SARS-CoV-2: ventilation improvement strategies in preparation for school re-opening
    David C Lung, MRCPCH (UK), FRCPath1; Mike YW Kwan, MSc (Applied Epidemiology) (CUHK), FHKAM (Paediatrics)2; CB Chow, MD, FHKAM (Paediatrics)3
    1 Department of Pathology, Queen Elizabeth Hospital/Hong Kong Children’s Hospital, Hong Kong
    2 Paediatric Infectious Disease Unit, Department of Paediatrics and Adolescent Medicine, Princess Margaret Hospital, Hong Kong
    3 Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong
     
    Corresponding author: Dr Mike YW Kwan (mike_kwan@hotmail.com)
     
     Full paper in PDF
     
     
    Airborne transmission of COVID-19
    Hong Kong has adopted a multifaceted approach to minimise the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the community since 2020. Measures currently implemented, which include mask wearing, social distancing, hand hygiene, and border controls, mainly address transmission by the droplet route. However, airborne transmission of SARS-CoV-2 in confined spaces has been largely overlooked.
     
    Short-range airborne transmission is currently recognised as a predominant route for transmission of SARS-CoV-2.1 The US Centers for Disease Control and Prevention have also acknowledged the importance of transmission of coronavirus disease 2019 (COVID-19) through inhalation of viruses in the air at distances farther than six feet (2 m).2 Several important factors contribute to increased risk, including: enclosed space with inadequate ventilation; increased exhalation of respiratory fluid (eg, shouting, singing, exercise); and prolonged exposure (>15 minutes).
     
    Enhancing ventilation in schools has been recognised as an important measure for re-opening of schools in multiple countries.3 In addition, a recent study in the US has demonstrated that mask wearing can markedly reduce COVID-19 outbreaks at schools.4
     
    Will airborne transmission happen at schools?
    After nearly 15 months of prolonged interruption of in-person learning since early 2020 in Hong Kong, the Education Bureau announced the resumption of face-to-face classes for all kindergartens and primary and secondary schools after the Easter holidays on 26 March 2021.5 However, other than the usual mandatory mask wearing and social distancing measures, there were no enhancements to infection control measures at schools. The compliance with mask wearing advice is often poor, especially in children; at least 13 outbreaks of upper respiratory tract infection, mostly caused by Rhinovirus, occurred between April and June 2021.6 This suggests that COVID-19 transmission chains could occur at schools despite the current measures, and that there is an urgent need to examine and enhance ventilation at schools.
     
    Although regulations pertaining to schools in Hong Kong state that “all school premises shall be adequately ventilated and lighted”,7 8 there is no clear definition or quantification of how well the ventilation should be. In the US, fresh air supply in classrooms (for ages 5-8 and ≥9 years) and other education facilities should be at least 5 L/s per person, in accordance with the American Society of Heating, Refrigerating and Air-Conditioning Engineers (ASHRAE) standard 62.1-2016.9 In Hong Kong, standards for new buildings recommend that fresh air provision in normally occupied spaces should exceed the minimum ASHRAE standard by at least 30%.10 Applied to the school setting, this would be equivalent to 6.5 L/s per person. The World Health Organization has recently stated that indoor ventilation should be 10 L/s per person (around 8-10.4 air changes per hour [ACH] depending on the ceiling height).11
     
    Potential solution
    A similar problem was encountered by the catering industry. Prior to March 2021, multiple clusters of COVID-19 cases occurred, resulting in restaurants being forced to suspend dine-in service or shorten business hours. To address the potential airborne transmission of COVID-19 in dine-in catering premises, the Hong Kong SAR Government decided to promote enhancement of ventilation. The current ventilation requirement for restaurants is 17 m3/h per person (around 3.8-4.9 ACH depending on ceiling height).12 Aiming to reduce the risk of airborne transmission of COVID-19 in mask-off indoor settings, the Government set a target of 6 ACH for these premises. A mandatory registration scheme was launched on 18 March 2021, whereby catering business operators were required to report whether their business premises attained ≥6 ACH. For premises unable to meet this requirement, air purifiers (with high-efficiency particulate arrestance filters or ultraviolet devices) had to be installed before 30 April 2021. The Government also formed a working group to promote compliance and ensure the smooth implementation of these requirements.13 As of July 2021, most dine-in restaurants met the requirements, and no large clusters of cases in dine-in restaurant settings have been reported since April 2021, despite many individuals confirmed to have COVID-19 visiting multiple restaurants during their infectious period.
     
    Schools, just like restaurants, are subject to the same risk, because compliance with mask wearing advice, especially among children, cannot be guaranteed at all times. Therefore, all possible measures should be optimised before the resumption of schools in September 2021. Air conditioning alone does not ensure adequate ventilation, since most are recirculating air and there may be insufficient fresh air to dilute the indoor air and contaminated particles. It is understandable that changing the heating, ventilation, and air conditioning system at schools may not be always possible, especially within such a short period of time. However, using the experience of restaurants in Hong Kong as an example, alternative means to improve ventilation can be adopted, such as high-efficiency particulate arrestance filters and ultraviolet-C devices.3 14 15
     
    With support from the Government and collaboration with architectural and engineering professionals, technology can be implemented to construct buildings with an infection resilient environment, using a combination of ventilation, air cleaning, and environmental monitoring. This approach could greatly reduce the chance of infection of the inhabitants and the environment.16
     
    Although a fully vaccinated population is the best defence against COVID-19, this will be unachievable within the short period of time before the next school term begins. It is time for relevant stakeholders to review the latest scientific evidence and international recommendations and to revise current policies, prioritising ventilation in schools as a major infection control measure for the safe re-opening of schools. Schools should act promptly and modify ventilation settings to prepare for the new term and the expected winter surge in COVID-19 cases.
     
    Author contributions
    All authors contributed to the editorial, approved the final version for publication, and take responsibility for its accuracy and integrity.
     
    Conflicts of interest
    DC Lung is a member of the “Working Group on Implementing the Requirement on Air Change or Air Purifiers in Dine-in Restaurants under Cap. 599F”. All other authors have disclosed no conflicts of interest.
     
    References
    1. To KK, Sridhar S, Chiu KH, et al. Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic. Emerg Microbes Infect 2021;10:507-35. Crossref
    2. Centers for Disease Control and Prevention. Scientific Brief: SARS-CoV-2 transmission. Available from: https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/sars-cov-2-transmission.html. Accessed 21 Jul 2021.
    3. Centers for Disease Control and Prevention. Ventilation in schools and childcare programs: how to use CDC building recommendations in your setting. Available from: https://www.cdc.gov/coronavirus/2019-ncov/community/schools-childcare/ventilation.html. Accessed 23 Jul 2021.
    4. Gettings J, Czarnik M, Morris E, et al. Mask use and ventilation improvements to reduce covid-19 incidence in elementary schools—Georgia, November 16-December 11, 2020. MMWR Morb Mortal Wkly Rep 2021;70:779-84. Crossref
    5. Government announces class arrangements after Easter holidays: Press release. 26 Mar 2021. Education Bureau, Hong Kong SAR Government. Available from: https://www.info.gov.hk/gia/general/202103/26/P2021032600480.htm. Accessed 1 Aug 2021.
    6. Centre for Health Protection, Department of Health, Hong Kong SAR Government. Media Room. Available from: https://www.chp.gov.hk/en/media/116/index.html. Accessed 21 Jul 2021.
    7. Department of Justice, Hong Kong SAR Government. Education Regulations (Cap. 279, section 84). Available from: https://www.elegislation.gov.hk/hk/cap279A. Accessed 1 Aug 2021.
    8. Education Bureau, Hong Kong SAR Government. Guidelines for registration of a new school. Available from: https://www.edb.gov.hk/attachment/en/sch-admin/sch-registration/about-sch-registration/2020%20Guidelines/1b_eguide-non-purpose-built_Dec%202020. pdf. Accessed 26 Aug 2021.
    9. ANSI/ASHRAE Standard 62.1-2019. Ventilation for Acceptable Indoor Air Quality; 2019.
    10. Hong Kong Green Building Council. BEAM Plus New Buildings Version 2.0 (2021 Edition). Available from: https://www.hkgbc.org.hk/eng/beam-plus/file/BEAMPlus_New_Buildings_v2_0.pdf. Accessed 1 Aug 2021.
    11. World Health Organization. Roadmap to improve and ensure good indoor ventilation in the context of COVID-19. Available from: https://www.who.int/publications/i/item/9789240021280. Accessed 1 Aug 2021.
    12. Department of Justice, Hong Kong SAR Government. Cap. 132 Public Health and Municipal Services Ordinance.
    13. Food and Environmental Hygiene Department, Hong Kong SAR Government. Guide on Compliance with Requirement on Air Change / Air Purifiers in Seating Areas of Dine-in Catering Premises. Available from: https://www.fehd.gov.hk/english/licensing/guide_general_reference/guide_on_compliance_with_requirement_on_air_change.html. Accessed 1 Aug 2021.
    14. Olsiewski PJ, Bruns R, Gronvall GK, et al. School Ventilation: A Vital Tool to Reduce COVID-19 Spread. The Johns Hopkins Center for Health Security; 2021.
    15. ASHRAE. Guidance for the re-opening of schools. Available from: https://www.ashrae.org/file%20library/technical%20resources/covid-19/guidance-for-the-re-opening-of-schools.pdf. Accessed 1 Aug 2021.
    16. Chartered Institution of Building Service Engineers. Infection resilient environments: buildings that keep us healthy and safe: initial report. Available from: https://www.raeng.org.uk/publications/reports/infection-resilient-environments. Accessed 1 Aug 2021.

    Pages